var title_f29_24_30080="Normal endoscopic view of open eustachian tube";
var content_f29_24_30080=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Normal endoscopic view of open eustachian tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal left eustachian tube in the open position. Dilated valve (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Poe DS, Gopen Q. Eustachian Tube Dysfunction. In Wackym PA: Ballenger's Textbook of Otolaryngology. Toronto: BC Decker, 2008. Copyright &copy; 2008 PMPH-USA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30080=[""].join("\n");
var outline_f29_24_30080=null;
var title_f29_24_30081="Gottrons sign 1 PI";
var content_f29_24_30081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gottron's sign in dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 229px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous, scaly eruption over the extensor surfaces of the metacarpophalangeal joints and digits in a patient with dermatomyositis. These lesions, called Gottron's sign, can mimic psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marc Miller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30081=[""].join("\n");
var outline_f29_24_30081=null;
var title_f29_24_30082="Mini-case session #6: Acute renal failure";
var content_f29_24_30082=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mini-case session #6: Acute renal failure",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30082/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30082/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30082/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30082/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30082/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30082/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/24/30082/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 28, 1995.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 77 year-old woman presents with weakness, anorexia, and fatigue for one week. One month ago, she had symptoms suggestive of a viral infection; at that time the plasma creatinine concentration was 1.0",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    She is now admitted because of increasing symptoms.",
"   </p>",
"   <p>",
"    Physical examination reveals a blood pressure of",
"    <span class=\"nowrap\">",
"     160/100.",
"    </span>",
"    The remainder of the examination is noncontributory: there is no edema or rash.",
"   </p>",
"   <p>",
"    Initial laboratory data include:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;BUN &nbsp;= &nbsp;98",
"    <span class=\"nowrap\">",
"     mg/dL",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma creatinine &nbsp;= &nbsp;10",
"    <span class=\"nowrap\">",
"     mg/dL",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma sodium &nbsp;= &nbsp;140",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma potassium &nbsp;= &nbsp;4.6",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Hematocrit &nbsp;= &nbsp;29 percent",
"    <br/>",
"    &nbsp; &nbsp; &nbsp;Urinalysis &nbsp;= &nbsp;trace protein by dipstick, benign sediment",
"   </p>",
"   <p>",
"    &nbsp;A. &nbsp;Is this acute or chronic renal failure? What factors help to make this decision if no prior history is available?",
"   </p>",
"   <p>",
"    &nbsp;B. &nbsp;What categories of renal disease (prerenal, postrenal, glomerular, vascular, or tubulointerstitial) can cause this type of renal failure with a normal urinalysis? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;C. &nbsp;Is the patient in sodium, water, and potassium balance? How might this be achieved in the presence of a marked decline in glomerular filtration rate? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CASE 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 66 year-old man with a past history of rheumatic heart disease, mitral regurgitation and aortic stenosis is admitted to the hospital with increasing shortness of breath. Physical examination reveals a pulse of",
"    <span class=\"nowrap\">",
"     120/min",
"    </span>",
"    and regular, blood pressure of",
"    <span class=\"nowrap\">",
"     120/70,",
"    </span>",
"    respiratory rate",
"    <span class=\"nowrap\">",
"     32/min,",
"    </span>",
"    estimated jugular venous pressure greater than 15 cmH2O, bilateral rales halfway up both lung fields, a holosystolic murmur at the apex, a systolic ejection murmur at the base, a tender enlarged liver with hepatojugular reflux, and 2+ pretibial and pedal edema.",
"   </p>",
"   <p>",
"    Chest x-ray shows cardiomegaly and pulmonary edema. EKG is suggestive of left ventricular hypertrophy. Admission laboratory studies include:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;BUN &nbsp;= &nbsp;86",
"    <span class=\"nowrap\">",
"     mg/dL",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma creatinine &nbsp;= &nbsp;1.9",
"    <span class=\"nowrap\">",
"     mg/dL",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma sodium &nbsp;= &nbsp;126",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma potassium &nbsp;= &nbsp;3.6",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma chloride &nbsp;= &nbsp;93",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma bicarbonate &nbsp;= &nbsp;23",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine sodium &nbsp;= &nbsp;12",
"    <span class=\"nowrap\">",
"     meq/L",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine creatinine &nbsp;= &nbsp;144",
"    <span class=\"nowrap\">",
"     mg/dL",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urine osmolality &nbsp;= &nbsp;423",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Urinalysis &nbsp;= &nbsp;benign",
"   </p>",
"   <p>",
"    &nbsp;A. &nbsp;Calculate the ratio of urine to plasma creatinine and fractional excretion of sodium. What do these parameters reflect and how are they helpful in the differential diagnosis of acute renal failure? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=see_link\">",
"     \"Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;B. &nbsp;What is the mechanism by which hyponatremia occurs in heart failure? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=see_link\">",
"     \"Hyponatremia in patients with heart failure\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    &nbsp;C. &nbsp;Consider the hormonal changes induced by the low cardiac output in heart failure. What changes will they have on renal blood flow and the glomerular filtration rate?",
"   </p>",
"   <p>",
"    In an effort to improve systemic hemodynamics and relieve vascular congestion and peripheral edema, the patient is treated with a loop diuretic,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    , and an angiotensin converting enzyme inhibitor. This regimen leads to a marked improvement in symptoms and in the patient's sense of well-being. However, 2 weeks later he develops nausea and vomiting and the following results are obtained:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;BUN &nbsp;= &nbsp;156",
"    <span class=\"nowrap\">",
"     mg/dL",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp; &nbsp;Plasma creatinine &nbsp;= &nbsp;6.7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;A. &nbsp;What effect would each of the drugs given have on the cardiac output? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=see_link\">",
"     \"Use of diuretics in patients with heart failure\"",
"    </a>",
"    ). What is the simplest method clinically to determine if a significant decline in cardiac output has occurred?",
"   </p>",
"   <p>",
"    &nbsp;B. &nbsp;What factors accounted for the acute deterioration in renal function? (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10069?source=see_link\">",
"     \"Renal effects of ACE inhibitors in heart failure\"",
"    </a>",
"    ).",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7249 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30082=[""].join("\n");
var outline_f29_24_30082=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CASE 2",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/17/8472?source=related_link\">",
"      Fractional excretion of sodium, urea, and other molecules in acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38742?source=related_link\">",
"      Hyponatremia in patients with heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10069?source=related_link\">",
"      Renal effects of ACE inhibitors in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/55/3962?source=related_link\">",
"      Use of diuretics in patients with heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_24_30083="Dyphylline and guaifenesin: Drug information";
var content_f29_24_30083=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dyphylline and guaifenesin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/12/18628?source=see_link\">",
"    see \"Dyphylline and guaifenesin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4110881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Difil-G&reg; 400",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F4110885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Expectorant;",
"     </li>",
"     <li>",
"      Phosphodiesterase Enzyme Inhibitor, Nonselective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F4110907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Asthma/bronchospasm:",
"     </b>",
"     Oral: Dyphylline 200 mg and guaifenesin 400 mg: One tablet 3-4 times daily (maximum: 2 tablets 3-4 times daily)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F4110908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F4110909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment provided in the manufacturer&rsquo;s labeling; dyphylline clearance is reduced in renal impairment and the half-life prolonged in anuria.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15822392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F4110866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.=",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Difil-G&reg; 400: Dyphylline 200 mg and guaifenesin 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F4110883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F4110910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after meals to decrease stomach irritation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F4110886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bronchial asthma and reversible bronchospasm associated with chronic bronchitis and emphysema",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F4110913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Circulatory failure, extrasystoles, flushing, hypotension, palpitation, tachycardia, ventricular arrhythmias",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Agitation, dizziness, drowsiness, headache, hyperexcitability, insomnia, irritability, restlessness, seizure (generalized tonic-clonic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, SIADH, uric acid serum concentration decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Diarrhea, epigastric pain, hematemesis, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular: Muscle twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Albuminuria, diuresis, hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Tachypnea",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F4110891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dyphylline, guaifenesin, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4110892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with severe cardiac disease including, acute myocardial injury, hypertension, and heart failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patient with peptic ulcer disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Status asthmaticus: Xanthine derivatives, including theophylline, are not indicated for the management of status asthmaticus.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F4110896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Theophylline Derivatives may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Theophylline Derivatives. Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Theophylline Derivatives may enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Theophylline Derivatives may enhance the adverse/toxic effect of Indacaterol. Theophylline Derivatives may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Theophylline Derivatives may decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancuronium: Theophylline Derivatives may enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium.  Management: Pancuronium dosage adjustment may be necessary to induce paralysis  in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F4110887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4110888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F4110890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9515536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take after meals to decrease stomach irritation.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Difil-G Forte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-100 mg/5 mL (240 mL): $65.98",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F4110902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dyphylline primarily causes bronchodilation by competitively inhibiting phosphodiesterases resulting in the increase of cyclic AMP and the relaxation of bronchial smooth muscles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Guaifenesin is thought to act as an expectorant by irritating the gastric mucosa and stimulating respiratory tract secretions, thereby increasing respiratory fluid volumes and decreasing phlegm viscosity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F4110903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8810 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-41F16B85B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30083=[""].join("\n");
var outline_f29_24_30083=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110881\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110885\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110907\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110908\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110909\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15822392\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110866\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110883\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110910\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110886\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110913\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110891\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110892\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299246\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110896\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110887\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110888\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110890\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9515536\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324113\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110902\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4110903\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8810\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8810|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/12/18628?source=related_link\">",
"      Dyphylline and guaifenesin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_24_30084="Hydrocodone and homatropine: Patient drug information";
var content_f29_24_30084=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydrocodone and homatropine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/33/34326?source=see_link\">",
"     see \"Hydrocodone and homatropine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hydromet&reg;;",
"     </li>",
"     <li>",
"      Tussigon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702259",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydrocodone, homatropine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694356",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (syrup) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect tablets from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12538 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FBD0C7583D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30084=[""].join("\n");
var outline_f29_24_30084=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180122\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017022\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017021\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017026\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017027\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017029\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017024\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017025\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017030\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017031\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/33/34326?source=related_link\">",
"      Hydrocodone and homatropine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_24_30085="Joint protection program for the neck";
var content_f29_24_30085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Joint protection program for the neck",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30085/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30085/contributors\">",
"     Maureen R Gecht-Silver, MPH, OTR/L",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30085/contributors\">",
"     Alison M Duncombe, PT, OCS, FAAOMPT",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30085/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30085/contributors\">",
"     Zacharia Isaac, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30085/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30085/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/24/30085/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of neck pain includes active treatment, rehabilitation, and joint protection. A joint protection program for the neck is indicated for patients with a rheumatologic disorder involving the neck to help prevent recurrent sprains and strains that add to inflammation and degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, it is fundamental in preventive joint care.",
"   </p>",
"   <p>",
"    The principles and guidelines for joint protection programs for the neck will be reviewed here. An overview of joint protection and the evaluation and treatment of neck pain are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35896?source=see_link\">",
"     \"Overview of joint protection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=see_link\">",
"     \"Evaluation of the patient with neck pain and cervical spine disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23113?source=see_link\">",
"     \"Treatment of neck pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF JOINT PROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following principles are the foundation of patient education in joint protection and are applicable to joint protection for the neck.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respect pain",
"     </li>",
"     <li>",
"      Distribute the load over stronger joints",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      larger surface areas",
"     </li>",
"     <li>",
"      Avoid maintaining the same joint position for prolonged periods",
"     </li>",
"     <li>",
"      Reduce excess body weight",
"     </li>",
"     <li>",
"      Use good posture and body mechanics",
"     </li>",
"     <li>",
"      Use the minimum amount of force necessary to complete the job",
"     </li>",
"     <li>",
"      Simplify work by using efficiency principles: plan, organize, and balance work with rest",
"     </li>",
"     <li>",
"      Remain active to maintain and increase strength and range of motion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These principles are derived from the simple, practical application of proper body mechanics, posture, and positioning of joints. Joint protection reduces local joint stress and preserves joint integrity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35896?source=see_link\">",
"     \"Overview of joint protection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Correct posture in sitting has been found to significantly reduce muscle activity, particularly in the jaw and posterior neck, compared with forward head positioning [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/2\">",
"     2",
"    </a>",
"    ]. Although these approaches have biologic plausibility, their effectiveness alone in prevention or treatment of work-related symptoms is uncertain. As an example, attention to posture did not produce a significant difference in musculoskeletal symptoms in a prospective trial in which computer users were the subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefits of joint protection techniques in patients with neck pain are demonstrated in the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 421 chronically disabled patients with work-related cervical spine disorders evaluated the effectiveness of ergonomic principles that included a comprehensive functional restoration program [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/4\">",
"       4",
"      </a>",
"      ]. Most were able to return to and remain at work, with low rates of recurrent injury or new surgery in the injured area and less use of health care resources following the intervention.",
"     </li>",
"     <li>",
"      Ergonomic training together with the use of an arm rest was more effective than instruction in correct posture alone for keyboard and video display users in a study that randomly assigned 182 employees working in a call-center to one of four interventions: ergonomics training only, training plus a trackball, training plus a forearm support, or training plus a trackball and forearm support [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/5\">",
"       5",
"      </a>",
"      ]. Ergonomic training plus the use of an armboard significantly reduced the one-year incidence of neck and shoulder disorders compared with ergonomic training alone (hazard ratio [HR] 0.49, 95% CI 0.24-0.97). The use of the armboard also reduced self reported neck and shoulder pain and right upper extremity pain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aggravating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aggravating factors are those habits and activities that can initiate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perpetuate soft tissue rheumatic pain and disability. Delving into the patient's routine at work, at home, and in sports is the starting point.",
"   </p>",
"   <p>",
"    As an example, office work that involves use of a video display terminal (VDT) is associated with a substantial annual incidence of neck pain. One study of those who used a VDT at work found that 34 percent experienced neck pain at some time during the year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/6\">",
"     6",
"    </a>",
"    ]. Other risk factors for neck pain were female sex, mental stress, and lack of exercise.",
"   </p>",
"   <p>",
"    Job strain is a subjective measure that increases when job demands are high and when job decision latitude is low. Increased job strain may predispose to neck pain. As an example, a prospective observational study of job strain (determined by questionnaire) among computer users compared pain and other musculoskeletal symptoms at baseline and after six months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/7\">",
"     7",
"    </a>",
"    ]. Self-reported job strain was associated with future musculoskeletal symptoms when compared with those who did not perceive job strain (HR 1.65, 95% CI 0.91-2.99). Among those reporting job strain, computer users in the highest strain-ratio category were at increased risk of neck and shoulder symptoms when compared with those in the lowest strain-ratio category (HR 1.52, 95% CI 0.88-2.62). Those with limited previous computer work also had more frequent symptoms.",
"   </p>",
"   <p>",
"    Ergonomic deficiencies in computer workstation design and use are common and have a deleterious effect on the user. Examples include use of nonadjustable chairs, sitting in bent and unsupported postures, and use of office tables for siting of computers. Attention to good workplace design helps to reduce posture-related pain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar problems, including poor resting posture, the act laying with the head propped forward on too-high pillows or the arm of a sofa, positions with the arms extended, or improper height of the computer terminal, are present in the home and in the workplace. Prolonged needle work, improper glasses, and improper lighting may contribute to neck pain. Falling asleep while reading and allowing the head to drop forward can also cause symptoms.",
"   </p>",
"   <p>",
"    Personality assessment may also be important. The patient who is a compulsive worker with the attitude, &ldquo;I'm going to finish this job if it kills me,&rdquo; must learn to respect the pain signals, to recognize potentially self-destructive behavior, and to let reason prevail. Telling a patient not to do a task may not be as helpful as guiding the patient to perform the task in a manner that puts less stress on joints. (See",
"    <a class=\"medical medical_review\" href=\"./temporomandibular-disorders-in-adults?source=see_link\">",
"     \"Temporomandibular disorders in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     GUIDELINES FOR HEAD AND NECK PROTECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following guidelines may be used to prevent further or recurrent head and neck injury in patients with disorders such as temporomandibular joint dysfunction syndrome, cervical pain syndromes, cervical nerve root impingement, and thoracic outlet syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Time on task",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid sitting or standing for more than 30 minutes at one time. Long periods of sitting can induce more neck strain than lifting heavy objects.",
"     </li>",
"     <li>",
"      Take frequent breaks during tasks in which the body does not move (eg, knitting, VDT use) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consider a sit-stand workstation. In a randomized trial of 60 young male office workers, musculoskeletal symptoms were reduced without loss of data entry efficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Increase physical activity",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Include tasks that allow the body greater movement (eg, sweeping).",
"     </li>",
"     <li>",
"      Manipulation or mobilization combined with exercise has been found to be more effective in short-term pain management and patient satisfaction than exercise alone [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intensive isometric neck strength training and endurance training of neck muscles, in addition to regular aerobic and stretching exercises, have been found to be effective in decreasing neck pain and disability and in increasing neck range of motion in female office workers with chronic neck pain [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Posture and alignment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Align the head, neck, and trunk during rest and activities.",
"     </li>",
"     <li>",
"      Avoid stressful head positions (eg, lying on a sofa with the head propped up, falling asleep in a chair and allowing the head to drop forward, and using more than one thin pillow).",
"     </li>",
"     <li>",
"      Align the entire trunk, chest, and head on a slanted wedge or a very large pillow while watching television or reading in a reclining position.",
"     </li>",
"     <li>",
"      Elevate the entire mattress or the head of the bed if it is necessary to sleep with the head elevated.",
"     </li>",
"     <li>",
"      Sleep on the side or the back. Avoid sleeping with arms above the head.",
"     </li>",
"     <li>",
"      Position the body and work materials in such a way that the neck remains straight during activities.",
"     </li>",
"     <li>",
"      Avoid the &ldquo;bird watcher's neck&rdquo; (also called VDT neck) that involves jutting the head forward as if watching birds through field glasses.",
"     </li>",
"     <li>",
"      Maintain the proper hand-to-eye work or reading distance of 16 to 20 inches.",
"     </li>",
"     <li>",
"      Organize workstations with adjustable chair, keyboard, and armrests, and consider an additional keyboard for portable (laptop) computer to improve neck and back posture and to reduce pain [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Reduce muscle tension and force",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use relaxation techniques or a bite spacer to prevent clenching of the jaw, which can cause muscle spasms in the neck.",
"     </li>",
"     <li>",
"      Perform stretching exercises to reduce muscle tension, strain,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      impingement.",
"     </li>",
"     <li>",
"      Work settings with high psychological stress promote negative mood and awkward posture; such settings increase the risk for upper extremity symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Body mechanics",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Store heavy items that are used daily no higher than the shoulders and no lower than the knees.",
"     </li>",
"     <li>",
"      Use a step stool when lifting heavy items from shelves higher than the shoulders.",
"     </li>",
"     <li>",
"      Be conscious of stressful head positions when concentrating, when driving, or when feeling tense.",
"     </li>",
"     <li>",
"      Place a computer screen so that eye level is aligned with the upper one-third of the display, and use a &ldquo;draft holder&rdquo; to place work at eye level next to the screen.",
"     </li>",
"     <li>",
"      Vary swim strokes and head position during swimming and water exercise.",
"     </li>",
"     <li>",
"      When working with arms overhead, position the body strategically so as to work upward and forward. Perform shoulder strengthening and spine extension exercises.",
"     </li>",
"     <li>",
"      Remain active to maintain strength and range of motion. Being physically active was cited by the Neck Pain Task Force as one of the few prognostic factors for controlling neck pain [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Strengthen the spinal extensor muscles to delay the progression of kyphosis that may occur in middle-aged women and that may contribute to neck pain [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adaptive equipment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use &ldquo;hands-free&rdquo; headsets or a speaker phone for prolonged or frequent telephone use.",
"     </li>",
"     <li>",
"      Use eye glasses with corrective lenses that are optimal for viewing the video display and reading materials at the distances described above. Glasses with gradually changing power (progressive lenses) may restrict neck motion more than use of bifocal or reading glasses.",
"     </li>",
"     <li>",
"      Use a broad arm board for keyboard work.",
"     </li>",
"     <li>",
"      When driving, the automobile should be equipped with side-curtain airbags [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/18\">",
"       18",
"      </a>",
"      ]; head restraints should be in a high and forward position [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30085/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"   </p>",
"   <p>",
"    Taylor MT. My Neck Hurts!: Nonsurgical Treatments for Neck and Upper Back Pain, Johns Hopkins Press 2010.",
"   </p>",
"   <p>",
"    Crepeau EB, Cohn ES, Boyt Schell BA. Willard and Spackman's Occupational Therapy, 11",
"    <sup>",
"     th",
"    </sup>",
"    , Lippincott Williams &amp; Wilkins 2009.",
"   </p>",
"   <p>",
"    Claiborne DK, Powell NJ, Reynolds-Lynch K. Ergonomics and Cumulative Trauma Disorders: A Handbook for Occupational Therapists, Singular Pub Group 1999.",
"   </p>",
"   <p>",
"    Musculoskeletal Disorders in the Workplace: Principles and Practice, Nordin M, Andersson GBJ, Pope MH (Eds), Mosby-Year Book 1997.",
"   </p>",
"   <p>",
"    Human Factors and Ergonomics Society",
"   </p>",
"   <p>",
"    Box 1369",
"   </p>",
"   <p>",
"    Santa Monica, CA 90406",
"   </p>",
"   <p>",
"    (310) 394-1811",
"   </p>",
"   <p>",
"    Website:",
"    <a class=\"external\" href=\"file://hfes.org/\">",
"     hfes.org/",
"    </a>",
"   </p>",
"   <p>",
"    Applied Ergonomics",
"   </p>",
"   <p>",
"    Elsevier Science Ltd.",
"   </p>",
"   <p>",
"    Langford Lane",
"   </p>",
"   <p>",
"    Kidlington",
"   </p>",
"   <p>",
"    Oxford, OX5 1GB,UK",
"   </p>",
"   <p>",
"    Website:",
"    <a class=\"external\" href=\"file://www.elsevier.com/locate/apergo\">",
"     www.elsevier.com/locate/apergo",
"    </a>",
"   </p>",
"   <p>",
"    US Department of Health and Human Services",
"   </p>",
"   <p>",
"    4676 Columbia Pkwy",
"   </p>",
"   <p>",
"    Cincinnati, OH 45226",
"   </p>",
"   <p>",
"    Website:",
"    <a class=\"external\" href=\"file://www.hhs.gov/\">",
"     www.hhs.gov/",
"    </a>",
"   </p>",
"   <p>",
"    American Industrial Hygiene Assn",
"   </p>",
"   <p>",
"    2700 Prosperity Ave, Ste 250",
"   </p>",
"   <p>",
"    Fairfax, VA 22031",
"   </p>",
"   <p>",
"    Website:",
"    <a class=\"external\" href=\"file://www.aiha.org/\">",
"     www.aiha.org/",
"    </a>",
"   </p>",
"   <p>",
"    Job Accommodation Network",
"   </p>",
"   <p>",
"    809 Allen Hall",
"   </p>",
"   <p>",
"    PO Box 6123",
"   </p>",
"   <p>",
"    West Virginia University",
"   </p>",
"   <p>",
"    Morgantown, WV 26506",
"   </p>",
"   <p>",
"    (800) 526-7234",
"   </p>",
"   <p>",
"    Website:",
"    <a class=\"external\" href=\"file://janweb.icdi.wvu.edu/\">",
"     janweb.icdi.wvu.edu/",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506689\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A joint protection program for the neck is indicated for patients with a rheumatologic disorder involving the neck to help reduce local joint stress, to preserve joint integrity, and to help prevent recurrent sprains and strains that add to inflammation and degeneration. Principles of joint protection are derived from the application of proper body mechanics, posture, and positioning of joints. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Principles of joint protection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial step in evaluation includes a detailed evaluation of the patient's routine at work, at home, and in sports and other activities. This evaluation should identify aggravating factors, such as habits and activities that have the potential to initiate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      perpetuate soft tissue rheumatic pain and disability. Examples of such aggravating factors include use of a video display terminal, job stress, ergonomic deficiencies in workplace design and use, and insufficient rest or breaks from work. Similar factors can be present in the home and in the workplace. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Aggravating factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should limit time on task in one position, whether sitting or standing, to no more than 30 minutes, taking regular breaks from activities in a single body position and performing activities involving movement. Being physically active is associated with control of neck pain. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Time on task'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Increase physical activity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Body mechanics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maintaining good posture and alignment of the head, neck, and trunk during rest and activities is important. This should include avoiding stressful head positions, and patients should sleep on the side or the back, while avoiding sleeping with arms above the head. The proper hand-to-eye work or reading distance of 16 to 20 inches should be maintained. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Posture and alignment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Efforts to reduce muscle tension and strain include the use of stretching exercises. Although there is conflicting evidence that exercise can prevent neck pain, both isometric strength training and dynamic endurance training have been found to decrease pain and disability in women with chronic neck pain. Additionally, relaxation techniques or a bite spacer can be used to prevent clenching of the jaw, which can cause muscle spasms in the neck. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Reduce muscle tension and force'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Increase physical activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proper body mechanics, including attention to proper lifting and positioning for physically stressful activities, should be maintained in activities at home and in the workplace. Shoulder strengthening and spine extension exercises are also beneficial. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Body mechanics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adaptive equipment, such as eye glasses appropriate for distance (eg, lenses designed to focus on a video monitor) and &ldquo;hands-free&rdquo; headsets or a speaker phone for prolonged or frequent telephone use, should be used to limit strain. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Adaptive equipment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20818249\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Robert P Sheon, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sheon RP, Orr PM. A joint protection guide for rheumatic disorders. Appendix B. In: Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd, Sheon RP, Moskowitz RW, Goldberg VM (Eds), Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/2\">",
"      McLean L. The effect of postural correction on muscle activation amplitudes recorded from the cervicobrachial region. J Electromyogr Kinesiol 2005; 15:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/3\">",
"      Gerr F, Marcus M, Monteilh C, et al. A randomised controlled trial of postural interventions for prevention of musculoskeletal symptoms among computer users. Occup Environ Med 2005; 62:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/4\">",
"      Wright A, Mayer TG, Gatchel RJ. Outcomes of disabling cervical spine disorders in compensation injuries. A prospective comparison to tertiary rehabilitation response for chronic lumbar spinal disorders. Spine (Phila Pa 1976) 1999; 24:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/5\">",
"      Rempel DM, Krause N, Goldberg R, et al. A randomised controlled trial evaluating the effects of two workstation interventions on upper body pain and incident musculoskeletal disorders among computer operators. Occup Environ Med 2006; 63:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/6\">",
"      Korhonen T, Ketola R, Toivonen R, et al. Work related and individual predictors for incident neck pain among office employees working with video display units. Occup Environ Med 2003; 60:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/7\">",
"      Hannan LM, Monteilh CP, Gerr F, et al. Job strain and risk of musculoskeletal symptoms among a prospective cohort of occupational computer users. Scand J Work Environ Health 2005; 31:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/8\">",
"      Shikdar AA, Al-Kindi MA. Office ergonomics: deficiencies in computer workstation design. Int J Occup Saf Ergon 2007; 13:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/9\">",
"      Mclean L, Tingley M, Scott RN, Rickards J. Computer terminal work and the benefit of microbreaks. Appl Ergon 2001; 32:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/10\">",
"      Klussmann A, Gebhardt H, Liebers F, Rieger MA. Musculoskeletal symptoms of the upper extremities and the neck: a cross-sectional study on prevalence and symptom-predicting factors at visual display terminal (VDT) workstations. BMC Musculoskelet Disord 2008; 9:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/11\">",
"      Husemann B, Von Mach CY, Borsotto D, et al. Comparisons of musculoskeletal complaints and data entry between a sitting and a sit-stand workstation paradigm. Hum Factors 2009; 51:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/12\">",
"      Miller J, Gross A, D'Sylva J, et al. Manual therapy and exercise for neck pain: a systematic review. Man Ther 2010; 15:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/13\">",
"      Ylinen J, Takala EP, Nyk&auml;nen M, et al. Active neck muscle training in the treatment of chronic neck pain in women: a randomized controlled trial. JAMA 2003; 289:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/14\">",
"      Maliska M, Bugajska J. The influence of occupational and non-occupational factors on the prevalence of musculoskeletal complaints in users of portable computers. Int J Occup Saf Ergon 2010; 16:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/15\">",
"      Harrington CB, Feuerstein M. Workstyle in office workers: ergonomic and psychological reactivity to work demands. J Occup Environ Med 2010; 52:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/16\">",
"      Carroll LJ, Hogg-Johnson S, C&ocirc;t&eacute; P, et al. Course and prognostic factors for neck pain in workers: results of the Bone and Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated Disorders. Spine (Phila Pa 1976) 2008; 33:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/17\">",
"      Ball JM, Cagle P, Johnson BE, et al. Spinal extension exercises prevent natural progression of kyphosis. Osteoporos Int 2009; 20:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/18\">",
"      Stuke LE, Nirula R, Gentilello LM, Shafi S. Protection against head injuries should not be optional: a case for mandatory installation of side-curtain air bags. Am J Surg 2010; 200:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30085/abstract/19\">",
"      Viano DC. Seat design principles to reduce neck injuries in rear impacts. Traffic Inj Prev 2008; 9:552.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7758 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30085=[""].join("\n");
var outline_f29_24_30085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H506689\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRINCIPLES OF JOINT PROTECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aggravating factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      GUIDELINES FOR HEAD AND NECK PROTECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Time on task",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Increase physical activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Posture and alignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Reduce muscle tension and force",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Body mechanics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adaptive equipment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H506689\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20818249\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35896?source=related_link\">",
"      Overview of joint protection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./temporomandibular-disorders-in-adults?source=related_link\">",
"      Temporomandibular disorders in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23113?source=related_link\">",
"      Treatment of neck pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_24_30086="Pathogenesis of secondary (AA) amyloidosis";
var content_f29_24_30086=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of secondary (AA) amyloidosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30086/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30086/contributors\">",
"     Peter D Gorevic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30086/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30086/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30086/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30086/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/24/30086/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amyloidosis is a generic term that refers to the predominantly extracellular tissue deposition of fibrils composed of low molecular weight subunits (5 to 25 kD) derived from any of a variety of serum proteins. These fibrils have a predominantly antiparallel beta-pleated sheet configuration; they can be identified on biopsy specimens by tinctorial properties that result from the binding of specific dyes, such as Congo red (leading to green birefringence under polarized light) and thioflavine T (producing an intense yellow-green fluorescence), and by electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All forms of amyloidosis are characterized by co-deposition of other substances, including [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum amyloid P component (SAP), a member of the pentraxin family that includes C-reactive protein",
"     </li>",
"     <li>",
"      Glycosaminoglycans, notably heparan sulfate",
"     </li>",
"     <li>",
"      Apolipoproteins (E and J)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Twenty-seven different precursor proteins are known to undergo transformation to a fibrillar configuration in association with specific disease states. Common examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum amyloid A (SAA) protein in reactive (secondary) or AA amyloidosis",
"     </li>",
"     <li>",
"      Monoclonal immunoglobulin light chains in primary or AL amyloidosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=see_link\">",
"       \"Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beta-2 microglobulin in dialysis-related amyloidosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=see_link\">",
"       \"Dialysis-related amyloidosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A number of different proteins in the genetic amyloidoses (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=see_link\">",
"       \"Genetic factors in the amyloid diseases\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These diverse proteins have little in common with regard to their primary structure or metabolism. Thus, consideration has been given to the role that cofactors, such as glycosaminoglycans and SAP, may play in amyloid formation. Such cofactors may have one or more of the following effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Modulation of fibrillogenesis by direct binding to specific domains of subunit proteins or their precursors",
"     </li>",
"     <li>",
"      Stabilization of the fibril and protection from degradation",
"     </li>",
"     <li>",
"      Localization to specific organs or tissue sites by binding to matrix components or receptor molecules",
"     </li>",
"     <li>",
"      Secondary effects on the metabolism of precursor proteins, leading to the accumulation of degradation products with amyloidogenic potential",
"     </li>",
"     <li>",
"      Modulation of proteolytic events that may facilitate fibril formation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathogenesis of AA amyloidosis is presented here. The clinical manifestations, diagnosis, and treatment of this disorder are discussed separately. (See appropriate topic reviews.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SERUM AMYLOID A PROTEIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic AA amyloid results from the deposition in tissue of serum amyloid A (SAA) protein, which is a major acute phase reactant [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Types",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several forms of SAA have been identified in serum. These include acute phase (SAA1 and SAA2) and constitutive (SAA4) isoforms, allelic variants, and post-translational modifications of these gene products [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/7\">",
"     7",
"    </a>",
"    ]. Acute phase SAA proteins (SAA1 and SAA2) are apolipoproteins, primarily associated with specific high-density lipoprotein (HDL), and are also expressed extrahepatically (eg, synovial membrane) in the absence of HDL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/8\">",
"     8",
"    </a>",
"    ]. SAA1 and SAA2 are inducible by interleukin 1 (IL-1), interleukin 6 (IL-6), tumor necrosis factor (TNF), lipopolysaccharide (LPS), and several transcription factors, notably including SAA activating Factor (SAF-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Studies have also examined the predominant effect of IL-6 in combination with other proinflammatory cytokines, providing a basis for the therapeutic use of monoclonal antibodies directed against this cytokine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    its receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both SAA1 and SAA2 are polymorphic proteins; however, most interest has focused on allelic forms of SAA1, which is the more important precursor for tissue AA deposition. SAA1 has three alleles, designated SAA1.1, SAA1.3, and SAA1.5, defined by amino acid substitutions at positions 52 and 57 of the molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/12\">",
"     12",
"    </a>",
"    ]. The frequency of these alleles varies between populations and may be associated with the occurrence of AA amyloidosis in diseases such as rheumatoid arthritis, with the level of SAA in blood, with clearance, with susceptibility to proteolytic cleavage by specific metalloproteinases, with severity of disease, and with response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Possible function",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAA proteins may serve an important function by increasing the affinity of high-density lipoproteins for macrophages and adipocytes during the acute phase response, a property termed reverse cholesterol metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Other properties include extracellular matrix binding [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/16\">",
"     16",
"    </a>",
"    ], chemoattractant activity for monocytes and lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/17\">",
"     17",
"    </a>",
"    ], induction of the release of proinflammatory cytokines and G-GSF from neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and platelet effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/18,20\">",
"     18,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ligands",
"    </span>",
"    &nbsp;&mdash;&nbsp;SAA binds specifically to several ligands, including cholesterol (residues 1 to 18 and 40 to 63 of SAA), high-density lipoprotein (residues 1 to 18), calcium (residues 48 to 51), laminin (residues 24 to 76), and",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"      heparin",
"     </a>",
"     /heparan",
"    </span>",
"    sulfate (two binding sites within residues 17 to 49 and 77 to 103); the last ligand, in particular, has been targeted for the development of therapeutic agents for the treatment of AA amyloid [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23383?source=see_link\">",
"     \"Treatment of secondary (AA) amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some SAA binding may occur selectively within the joint space of patients with rheumatoid arthritis, as both acute phase and constitutive isoforms of SAA appear to be synthesized by synovial tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/8,22\">",
"     8,22",
"    </a>",
"    ]. High levels of both SAA and its receptor, formyl peptide receptor-like 1 (FPRL1), have been demonstrated in the rheumatoid synovium, and a link to leukocyte infiltration, including the influx of CCR6-expressing Th17 cells, was confirmed by the ability of SAA to upregulate CCR20 expression of rheumatoid arthritis (RA) synoviocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/23\">",
"     23",
"    </a>",
"    ]. Inhibition of IL-6-mediated induction of acute phase SAA in rheumatoid synovium by",
"    <span class=\"nowrap\">",
"     JAK/STAT",
"    </span>",
"    inhibitors being developed for clinical use provides another mechanism for abrogating SAA that may have potential for use in inflammatory arthritis, as well as in AA amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS OF AA AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common causes of AA amyloidosis are rheumatoid arthritis, chronic infections (particularly in underdeveloped countries), and autoinflammatory disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=see_link\">",
"     \"Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AA amyloid occurs spontaneously in various animal species and can be induced by chronic inflammatory stimuli. The best-studied model for this disease is amyloid induction by",
"    <span class=\"nowrap\">",
"     casein/azocasein",
"    </span>",
"    injections in certain genetically susceptible strains of mice [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/27\">",
"     27",
"    </a>",
"    ]. Although most animal models for AA amyloid parallel human disease with predominant fibril deposition in spleen, liver, and kidney, chickens develop a unique articular amyloidosis when injected with Enterococcus faecalis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Principal pathogenic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon findings in these animal models and results in patients, the principal pathogenic factors in AA amyloidosis appear to be the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/26,30\">",
"     26,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overproduction of both HDL-associated and lipid-free SAA as a consequence of acute and chronic inflammation",
"     </li>",
"     <li>",
"      Proteolytic processing of SAA to AA, with a major cleavage occurring at position 76, thereby releasing the carboxyterminal third of the molecule [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/31\">",
"       31",
"      </a>",
"      ]. The in vitro demonstration of internalization of SAA by macrophages, followed by intracellular proteolysis, and later by release of amyloidogenic peptides into the extracellular space [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/32\">",
"       32",
"      </a>",
"      ], suggests that these events precede fibril formation. However, there is still uncertainty about the order of events in vivo [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intrinsic fibrillogenic properties of the molecule [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Increased synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased synthesis of SAA with inflammation, which may be due to elevated levels of proinflammatory cytokines. With RA, for example, this increase in cytokine levels correlates with synovitis, which, in turn, may stimulate synoviocytes to produce SAA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/8,17,22,35\">",
"     8,17,22,35",
"    </a>",
"    ]. These events lead to elevated levels in joint fluid relative to serum [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, SAA may directly potentiate rheumatoid inflammation via the induction of matrix metalloproteinases (MMP1 and MMP3) by synovial cells and chondrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/22,36\">",
"     22,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of increased SAA synthesis has been demonstrated by the correlation between the serum SAA concentration and disease course in patients with established AA amyloidosis. This was illustrated in a report of 80 patients with AA amyloid (mostly due to juvenile idiopathic arthritis or to rheumatoid arthritis) who were prospectively followed for a median for four years; the systemic amyloid load was assessed by yearly SAP scintigraphy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/37\">",
"     37",
"    </a>",
"    ]. The following findings were noted (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23383?source=see_link\">",
"     \"Treatment of secondary (AA) amyloidosis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Forty-two patients had median serum SAA concentration within the reference range (&lt;10",
"      <span class=\"nowrap\">",
"       mg/L);",
"      </span>",
"      amyloid deposits regressed in 25 and stabilized in 14. Among patients with renal disease at baseline, proteinuria typically fell while the serum creatinine concentration was either stable or improved. Two patients who required dialysis remained on dialysis.",
"     </li>",
"     <li>",
"      The outcomes were variable in the other patients. However, among those in whom the serum SAA was persistently above 50",
"      <span class=\"nowrap\">",
"       mg/L,",
"      </span>",
"      the amyloid load usually increased, and organ function deteriorated. In one patient who underwent renal transplantation, proteinuria and renal amyloid deposits recurred within 36 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Amyloid deposition increased rapidly in patients with relapse of the underlying inflammatory disease. This observation is consistent with an underlying susceptibility to amyloidosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;All forms of AA amyloidosis are associated with increased levels of SAA in blood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/38\">",
"     38",
"    </a>",
"    ]. In rheumatoid arthritis, however, SAA levels are increased in both patients with and those without amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/39\">",
"     39",
"    </a>",
"    ]. This indicates that additional factors (perhaps genetic) must be involved in pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/40,41\">",
"     40,41",
"    </a>",
"    ], a feature of pathogenesis underscored by the variable incidence of AA amyloidosis complicating hereditary autoinflammatory disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/42\">",
"     42",
"    </a>",
"    ]. Other factors include aberrant degradation of serum amyloid A to AA protein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/43\">",
"     43",
"    </a>",
"    ] and the accumulation of proteolytic cleavage products in blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intrinsic properties",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type and size of the fragments that are formed may also determine both the amyloidogenic potential and the site of tissue deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Biochemical analysis suggests that smaller fragments are more likely to deposit in the glomeruli, while larger fragments may preferentially deposit in the blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Accelerated Deposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;In murine models of amyloidosis, the deposition phase of disease can be greatly accelerated by Amyloid Enhancing Factor (AEF), an activity which has been partially linked to AA fibrils, peptides, and oligomers and which is transmissible between animals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30086/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]; the relevance of these observations to the induction of AA amyloid in susceptible individuals with inflammatory diseases remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10817717\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Amyloidosis is a general term that refers to the predominantly extracellular tissue deposition of fibrils composed of low molecular weight subunits (5 to 25 kD) derived from any of more than two dozen diverse serum proteins; these proteins have little in common with regard to their primary structure or metabolism. The fibrils have a predominantly antiparallel beta-pleated sheet configuration; they can be identified on biopsy specimens by tinctorial properties that result from the binding of specific dyes, such as Congo red. All forms of amyloidosis are characterized by co-deposition of other substances, and cofactors may play a role in amyloid formation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic AA amyloid results from the deposition in tissue of serum amyloid A (SAA) protein, which is a major acute phase reactant. SAA proteins may function to increase the affinity of high-density lipoproteins (HDL) for macrophages and adipocytes during the acute phase response. SAA binds specifically to several ligands, including cholesterol, HDL, calcium, laminin, and",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"       /heparan",
"      </span>",
"      sulfate. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Serum amyloid a protein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common causes of AA amyloidosis are rheumatoid arthritis, chronic infections (particularly in underdeveloped countries), and autoinflammatory disorders. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Pathogenesis of AA amyloidosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal pathogenic factors in AA amyloidosis include overproduction of both HDL-associated and lipid-free SAA as a consequence of acute and chronic inflammation; proteolytic processing of SAA to AA, which releases the carboxyterminal third of the molecule and which may involve internalization of SAA by macrophages, intracellular proteolysis, and release of amyloidogenic peptides into the extracellular space; and intrinsic fibrillogenic properties of the molecule. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Principal pathogenic factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/1\">",
"      Pinney JH, Hawkins PN. Amyloidosis. Ann Clin Biochem 2012; 49:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/2\">",
"      Alexandrescu AT. Amyloid accomplices and enforcers. Protein Sci 2005; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/3\">",
"      Gallo G, Wisniewski T, Choi-Miura NH, et al. Potential role of apolipoprotein-E in fibrillogenesis. Am J Pathol 1994; 145:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/4\">",
"      Kisilevsky R, Ancsin JB, Szarek WA, Petanceska S. Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 2007; 14:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/5\">",
"      Husby G, Stenstad T, Magnus JH, et al. Interaction between circulating amyloid fibril protein precursors and extracellular tissue matrix components in the pathogenesis of systemic amyloidosis. Clin Immunol Immunopathol 1994; 70:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/6\">",
"      Tennent GA, Lovat LB, Pepys MB. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci U S A 1995; 92:4299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/7\">",
"      Kisilevsky R, Manley PN. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid 2012; 19:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/8\">",
"      O'Hara R, Murphy EP, Whitehead AS, et al. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum 2004; 50:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/9\">",
"      Thorn CF, Lu ZY, Whitehead AS. Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 2004; 59:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/10\">",
"      Ray A, Shakya A, Kumar D, et al. Inflammation-responsive transcription factor SAF-1 activity is linked to the development of amyloid A amyloidosis. J Immunol 2006; 177:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/11\">",
"      Yoshizaki K. Pathogenic role of IL-6 combined with TNF-&alpha; or IL-1 in the induction of acute phase proteins SAA and CRP in chronic inflammatory diseases. Adv Exp Med Biol 2011; 691:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/12\">",
"      Sipe J. Revised nomenclature for serum amyloid A (SAA). Nomenclature Committee of the International Society of Amyloidosis. Part 2. Amyloid 1999; 6:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/13\">",
"      Obici L, Raimondi S, Lavatelli F, et al. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009; 61:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/14\">",
"      van der Westhuyzen DR, de Beer FC, Webb NR. HDL cholesterol transport during inflammation. Curr Opin Lipidol 2007; 18:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/15\">",
"      Poitou C, Divoux A, Faty A, et al. Role of serum amyloid a in adipocyte-macrophage cross talk and adipocyte cholesterol efflux. J Clin Endocrinol Metab 2009; 94:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/16\">",
"      Ancsin JB, Kisilevsky R. Characterization of high affinity binding between laminin and the acute-phase protein, serum amyloid A. J Biol Chem 1997; 272:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/17\">",
"      Mullan RH, Bresnihan B, Golden-Mason L, et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum 2006; 54:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/18\">",
"      Lee HY, Kim SD, Shim JW, et al. LL-37 inhibits serum amyloid A-induced IL-8 production in human neutrophils. Exp Mol Med 2009; 41:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/19\">",
"      He RL, Zhou J, Hanson CZ, et al. Serum amyloid A induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009; 113:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/20\">",
"      Urieli-Shoval S, Shubinsky G, Linke RP, et al. Adhesion of human platelets to serum amyloid A. Blood 2002; 99:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/21\">",
"      Ancsin JB, Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999; 274:7172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/22\">",
"      Vallon R, Freuler F, Desta-Tsedu N, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001; 166:2801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/23\">",
"      Migita K, Koga T, Torigoshi T, et al. Serum amyloid A protein stimulates CCL20 production in rheumatoid synoviocytes. Rheumatology (Oxford) 2009; 48:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/24\">",
"      Migita K, Koga T, Komori A, et al. Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium. J Rheumatol 2011; 38:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/25\">",
"      Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356:2361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/26\">",
"      Grateau G. Musculoskeletal disorders in secondary amyloidosis and hereditary fevers. Best Pract Res Clin Rheumatol 2003; 17:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/27\">",
"      Gruys E, Snel FW. Animal models for reactive amyloidosis. Baillieres Clin Rheumatol 1994; 8:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/28\">",
"      Landman WJ. Amyloid arthropathy in chickens. Vet Q 1999; 21:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/29\">",
"      Sevimli A, Misirliolu D, Yaci A, et al. The role of chicken IL-1beta, IL-6 and TNF-alpha in the occurrence of amyloid arthropathy. Vet Res Commun 2008; 32:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/30\">",
"      Yakar S, Livneh A, Kaplan B, Pras M. The molecular basis of reactive amyloidosis. Semin Arthritis Rheum 1995; 24:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/31\">",
"      R&ouml;cken C, Menard R, B&uuml;hling F, et al. Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis 2005; 64:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/32\">",
"      Kinkley SM, Bagshaw WL, Tam SP, Kisilevsky R. The path of murine serum amyloid A through peritoneal macrophages. Amyloid 2006; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/33\">",
"      Westermark GT, Engstr&ouml;m U, Westermark P. The N-terminal segment of protein AA determines its fibrillogenic property. Biochem Biophys Res Commun 1992; 182:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/34\">",
"      Yamada T, Kluve-Beckerman B, Liepnieks JJ, Benson MD. Fibril formation from recombinant human serum amyloid A. Biochim Biophys Acta 1994; 1226:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/35\">",
"      Ray A, Schatten H, Ray BK. Activation of Sp1 and its functional co-operation with serum amyloid A-activating sequence binding factor in synoviocyte cells trigger synergistic action of interleukin-1 and interleukin-6 in serum amyloid A gene expression. J Biol Chem 1999; 274:4300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/36\">",
"      Lee HY, Kim MK, Park KS, et al. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun 2005; 330:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/37\">",
"      Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/38\">",
"      Gertz MA, Skinner M, Sipe JD, et al. Serum amyloid A protein and C-reactive protein in systemic amyloidosis. Clin Exp Rheumatol 1985; 3:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/39\">",
"      De Beer FC, Mallya RK, Fagan EA, et al. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982; 2:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/40\">",
"      Ajiro J, Narita I, Sato F, et al. SAA1 gene polymorphisms and the risk of AA amyloidosis in Japanese patients with rheumatoid arthritis. Mod Rheumatol 2006; 16:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/41\">",
"      Utku U, Dilek M, Akpolat I, et al. SAA1 alpha/alpha alleles in Beh&ccedil;et's disease related amyloidosis. Clin Rheumatol 2007; 26:927.",
"     </a>",
"    </li>",
"    <li>",
"     Ombrello AK, Aksentijevich I. AA amyloidosis. In: Amyloid and Related Disorders: Surgical Pathology and Clinical Correlations, Pickens MM.  (Ed), Springer, 2012. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/43\">",
"      Kluve-Beckerman B, Liepnieks JJ, Wang L, Benson MD. A cell culture system for the study of amyloid pathogenesis. Amyloid formation by peritoneal macrophages cultured with recombinant serum amyloid A. Am J Pathol 1999; 155:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/44\">",
"      Migita K, Eguchi K, Tsukada T, et al. Increased circulating serum amyloid A protein derivatives in rheumatoid arthritis patients with secondary amyloidosis. Lab Invest 1996; 75:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/45\">",
"      Westermark GT, Westermark P, Sletten K. Amyloid fibril protein AA. Characterization of uncommon subspecies from a patient with rheumatoid arthritis. Lab Invest 1987; 57:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/46\">",
"      Westermark GT, Sletten K, Westermark P. Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol 1989; 30:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/47\">",
"      Senthilkumar S, Chang E, Jayakumar R. Diffusible amyloid oligomers trigger systemic amyloidosis in mice. Biochem J 2008; 415:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30086/abstract/48\">",
"      Westermark GT, Westermark P. Serum amyloid A and protein AA: molecular mechanisms of a transmissible amyloidosis. FEBS Lett 2009; 583:2685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5619 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30086=[""].join("\n");
var outline_f29_24_30086=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10817717\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SERUM AMYLOID A PROTEIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Types",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Possible function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ligands",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS OF AA AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Principal pathogenic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Increased synthesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Processing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intrinsic properties",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Accelerated Deposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10817717\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/14/33000?source=related_link\">",
"      Causes and diagnosis of secondary (AA) amyloidosis and relation to rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5609?source=related_link\">",
"      Dialysis-related amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/10/42153?source=related_link\">",
"      Genetic factors in the amyloid diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/62/35815?source=related_link\">",
"      Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23383?source=related_link\">",
"      Treatment of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_24_30087="Abdominal aortic aneurysm with aortocaval fistula";
var content_f29_24_30087=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F87338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F87338&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Abdominal aortic aneurysm with aortocaval fistula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The aortograms (A, C red overlay) show a saccular infrarenal aortic aneurysm. Premature filling of the inferior&nbsp;vena cava&nbsp;(B, D blue overlay) is consistent with an aortocaval fistula, which is due to AAA rupture.",
"    <div class=\"footnotes\">",
"     <p>",
"      AAA: abdominal aortic aneurysm.",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30087=[""].join("\n");
var outline_f29_24_30087=null;
var title_f29_24_30088="Endoscopic ultrasound-guided celiac plexus and ganglia interventions";
var content_f29_24_30088=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic ultrasound-guided celiac plexus and ganglia interventions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30088/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30088/contributors\">",
"     Michael J Levy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30088/contributors\">",
"     Maurits J Wiersema, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30088/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30088/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30088/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30088/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/24/30088/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cancer and chronic pancreatitis are commonly associated with intense and often refractory pain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Non-narcotic medical therapies are often inadequate, and opioids commonly induce nausea, constipation, and other side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Non-pharmacologic therapies are commonly administered with the aim of improving pain control and quality of life, while reducing the risk of drug-induced side effects. Such therapies include celiac plexus neurolysis (CPN) with injection of alcohol in patients with pancreatic cancer or celiac plexus block (CPB) using steroids in patients with chronic pancreatitis.",
"   </p>",
"   <p>",
"    This topic review will provide an overview of CPN and CPB in the management of pain occurring secondary to pancreatic cancer and chronic pancreatitis, respectively, while focusing on endosonographic methods. It will also briefly review other applications of endoscopic ultrasound guided neurolysis, as well as emerging data concerning direct celiac ganglia neurolysis (CGN) and block (CGB), the most recently introduced technical variation of the standard technique.",
"   </p>",
"   <p>",
"    The American Gastroenterological Association (AGA) technical review for the overview of the management of pain in patients with chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/5\">",
"     5",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    . The clinical manifestations and diagnosis of pancreatic cancer, chronic pancreatitis, and an overview of palliative treatments for pancreatic cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic pancreatitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17735?source=see_link\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the terms \"celiac plexus\" and \"splanchnic nerves\" are often used interchangeably, they are anatomically distinct structures [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The splanchnic nerves are located above and posterior to the diaphragm and anterior most often to the 12th thoracic vertebra. The celiac plexus is located below and anterior to the diaphragm and surrounds the origin of the celiac trunk. The celiac plexus is comprised of a dense network of ganglia and interconnecting fibers. Celiac ganglia are typically located between T12 and L2 and, in most patients, two to five ganglia are present [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/6\">",
"     6",
"    </a>",
"    ]. The celiac plexus transmits the sensation of pain for the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/9\">",
"     9",
"    </a>",
"    ]. The nerves that supply the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/10\">",
"     10",
"    </a>",
"    ] receive nociceptive stimulation and then transmit this pain information to the celiac plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/11\">",
"     11",
"    </a>",
"    ]. Stimuli reach the thalamus and cortex of the brain and this information is perceived as pain. Descending inhibitory mechanisms may also modulate the ascending pain information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NON-EUS METHODS (FOR CELIAC \"PLEXUS\" NEUROLYSIS AND BLOCK)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPN and CPB can be performed percutaneously, surgically, or under endosonographic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The retrocrural or classic approach involves injection of the solution so that diffusion occurs over the splanchnic nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/15\">",
"     15",
"    </a>",
"    ]. Modifications have been created in an attempt to improve the accuracy of needle placement and pain relief, while reducing procedure-related complications. These techniques differ with respect to the route of needle insertion, use of radiologic guidance versus a blind procedure, and chemical composition of the injectate. The anterocrural or \"true\" CPN results in injection anterior to the diaphragm thereby diffusing over the celiac ganglia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Efficacy for pancreatic cancer pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;While CPN is considered safe, it provides limited benefit in terms of the degree and duration of pain relief and little advance has been made since the original description in 1914 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/15\">",
"     15",
"    </a>",
"    ]. In a meta-analysis of 24 studies with 1145 patients who were treated with percutaneous CPN for the palliation of cancer pain (63 percent with pancreatic cancer), good to excellent pain relief was noted in 70 to 90 percent of patients up to three months after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more recent meta-analysis examined six randomized trials with 358 patients undergoing percutaneous celiac plexus block for pancreatic cancer pain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/17\">",
"     17",
"    </a>",
"    ]. At four weeks, patients in the treatment arm had a significant improvement in pain compared with the control arm. The difference between the treatment and control arms was -0.42 on a 10-point visual analog scale (with lower values corresponding to better pain control). The difference at eight weeks was -0.44. In addition, opioid consumption was significantly lower in the treatment arm.",
"   </p>",
"   <p>",
"    The following illustrate the range of findings in individual reports.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective, randomized, double-blind, placebo-controlled study of 137 patients with unresectable pancreatic cancer who had surgical chemical splanchnicectomy, mean pain scores were significantly lower in the CPN group compared with placebo at two, four, and six months after the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another controlled trial included 100 patients with pain from unresectable pancreatic cancer who were randomly assigned to percutaneously administered CPN or systemic analgesic therapy alone with a sham injection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/19\">",
"       19",
"      </a>",
"      ]. All patients could receive additional opioids as needed. CPN improved pain relief but did not affect quality of life or survival. Opioid consumption and the frequency of opioid side effects were similar.",
"     </li>",
"     <li>",
"      A double-blind study involving 24 patients found that percutaneously administered CPN was associated with a significant reduction in analgesic consumption and drug-related side effects compared with patients treated with drugs alone [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A fourth study suggested that percutaneously administered CPN combined with systemic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      may prevent deterioration in quality of life by improving the duration of the analgesic effect and by reducing the morphine dose and side effects compared with treatment with NSAIDs and morphine alone [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A fifth study examined the efficacy of laparoscopic CPB in patients with pancreatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/22\">",
"       22",
"      </a>",
"      ]. The study included 20 patients who were undergoing",
"      <span class=\"nowrap\">",
"       diagnostic/staging",
"      </span>",
"      laparoscopy for unresectable pancreatic cancer. Following CPB, patients reported significant improvement in their pain compared with baseline (mean visual analog score of 5.7 prior to treatment and 2.7 at postoperative week four).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The specific approach does not appear to have a major influence on clinical outcomes, at least among studies evaluating percutaneous approaches. The meta-analysis described above concluded that despite a few reports favoring one technique over another, efficacy of pain relief was not influenced by the technical approach or the use of radiologic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Efficacy for chronic pancreatitis pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies evaluating percutaneous CPB for controlling pain from chronic pancreatitis have been small retrospective case series and have reported marginal benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. One study found that percutaneous CPN effectively relieved pain associated with malignant disease, but was not as effective for benign disease (73 versus 37 percent response) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/27\">",
"     27",
"    </a>",
"    ]. While limited data suggest percutaneous CPN produces short-term pain relief (weeks to months), extended pain relief typically requires repeat therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EUS METHODS (FOR PERFORMING CELIAC \"PLEXUS\" NEUROLYSIS AND BLOCK)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPN has been performed under EUS guidance, which compared with the percutaneous approaches, has the theoretical benefits of enhancing needle localization and spread of the injectate, minimizing complications and improving pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients are questioned regarding allergies and use of anticoagulants. Informed consent is obtained with specific attention to the unique complications associated with",
"    <span class=\"nowrap\">",
"     CPN/CPB.",
"    </span>",
"    The procedure is performed on an outpatient basis using conscious sedation, unless analgesic consumption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    comorbidities require monitored anesthesia care. Patients are initially hydrated with 500 to 1000 mL normal saline to minimize the risk of hypotension. Throughout the procedure patients are continuously monitored by an automated noninvasive blood pressure device and pulse oximeter.",
"   </p>",
"   <p>",
"    Linear array endosonographic imaging (GF-UC30P, Olympus Corporation, Center Valley, PA; GF UC140P-AL5 or GF UC 160 PAT8, Pentax Precision Instruments, Orangeburg, NY) from the posterior lesser curve of the gastric fundus permits identification of the aorta, which appears in a longitudinal plane (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77966 \" href=\"UTD.htm?4/30/4576\">",
"     image 1",
"    </a>",
"    ). The aorta is traced distally to the celiac trunk, which is the first major branch below the diaphragm.",
"   </p>",
"   <p>",
"    It was initially believed that the celiac plexus could not be identified as a discrete structure, but instead located based upon its position relative to the celiac trunk. However, it is now appreciated that celiac plexus can be recognized directly (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/28\">",
"     28",
"    </a>",
"    ]. Color Doppler is used to confirm the vascular nature of the adjacent structures. A 22-gauge needle is primed with saline to remove air and then placed through the biopsy channel and affixed to the hub.",
"   </p>",
"   <p>",
"    A dedicated 20-gauge needle with a \"spray\" needle with multiple side holes is available, which facilitates spread of the injected material (EUSN-20-CPN: Cook Endoscopy, Winston-Salem, NC). The selected needle is inserted under EUS guidance immediately adjacent and anterior to the lateral aspect of the aorta at the level of the celiac trunk (",
"    <a class=\"graphic graphic_figure graphicRef81618 \" href=\"UTD.htm?30/28/31170\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79530 \" href=\"UTD.htm?28/8/28801\">",
"     image 2",
"    </a>",
"    ). The needle is flushed with 3cc of normal saline to remove any tissue acquired during insertion. An aspiration test is performed to rule out vessel penetration prior to each injection. For CPN in pancreatic cancer patients, 10 mL (0.25 percent) of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    is injected followed by 10 mL dehydrated (98 percent) alcohol. The alcohol, which produces an echogenic cloud, may lead to discomfort despite sedation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57496 \" href=\"UTD.htm?19/44/20163\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Before withdrawing the needle, it should be flushed with 3 mL normal saline to prevent seeding of the needle track with alcohol, which may produce transient severe postprocedure pain. The entire process is then repeated on the opposite side of the aorta. Occasionally, altered anatomy resulting from significant lymphadenopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bulky tumors may require injection of the entire solution into one \"unilateral\" site. Left-sided unilateral injection is more likely to be associated with insufficient pain relief. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Efficacy for pancreatic cancer pain'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    After the procedure, which takes about 15 minutes, the vital signs are monitored for two hours. Prior to discharge, the blood pressure is checked in both a supine and erect position to assess for orthostasis.",
"   </p>",
"   <p>",
"    An alternative approach that has been described for patients with advanced abdominal cancer involves EUS-guided broad plexus neurolysis (BPN), in which the injection is performed at the level of the superior mesenteric artery, resulting in a broader distribution of neurolysis. In one trial with 67 patients assigned to either conventional CPN or BPN, patients in the BPN group had significantly better short- and long-term pain relief [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For CPB in patients with chronic pancreatitis, some authorities substitute a steroid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    suspension 40 mg-bilateral, 80-unilateral, Fujisawa USA, Deerfield, IL) in place of alcohol. Although use in patients with benign disease is controversial, a few centers administer a small volume of alcohol (4cc-bilateral, 8cc-unilateral) in addition to steroid to increase the neurolysis. If alcohol, which is bactericidal, is not given along with the steroid, we suggest administering broad-spectrum antibiotics, particularly if the patient is receiving acid-suppressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Efficacy for pancreatic cancer pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of small trials have evaluated EUS CPN for pancreatic cancer pain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. In one meta-analysis, EUS CPN decreased pain by a mean visual analog score of 0.6 (95% CI, 0.37-0.82) at eight weeks in cases compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/12\">",
"     12",
"    </a>",
"    ]. In a second meta-analysis, the proportion of patients with pain relief was 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/32\">",
"     32",
"    </a>",
"    ]. In the second meta-analysis, it was noted that patients who had injections on both sides of the celiac artery had a higher rate of pain relief than those who only received injections on one side (85 versus 46 percent). A third meta-analysis included 119 patients and found that EUS CPN alleviated abdominal pain in 73 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early use of CPN in patients with inoperable cancer may improve pain relief compared with conventional pain management. In a randomized trial, 580 patients with suspected pancreatic adenocarcinoma with related pain underwent EUS-guided fine-needle aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/34\">",
"     34",
"    </a>",
"    ]. Inoperable adenocarcinoma was found in 96 patients, who were assigned to either CPN or conventional pain management. At three months, patients treated with CPN had significantly greater pain relief, with a trend toward lower",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    consumption. There was no difference between the groups in quality of life scores or survival.",
"   </p>",
"   <p>",
"    A study of 47 patients identified factors associated with poor responses to CPN [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/35\">",
"     35",
"    </a>",
"    ]. Insufficient pain relief was more likely among patients with direct tumor invasion of the celiac plexus compared with those who lacked direct invasion (73 versus 28 percent) and among those in whom ethanol was only distributed to the left side of the celiac plexus (47 versus 6 percent).",
"   </p>",
"   <p>",
"    No large trials have directly compared EUS compared with percutaneous approaches, limiting the ability to directly compare their efficacy and safety. Nevertheless, EUS-guided CPN performed for the palliation of pancreatic cancer pain appears to be as safe and effective as CPN performed by other techniques. Furthermore, an advantage of the EUS approach is that it can be performed while staging and obtaining biopsies of the tumor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Efficacy for chronic pancreatitis pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating experience suggests that EUS guided celiac plexus block (CPB) performed with steroid injection rather than ethanol may be effective for the control of pain related to chronic pancreatitis, although its role has not yet been well established.",
"   </p>",
"   <p>",
"    In two meta-analyses, the rate of pain relief for patients with chronic pancreatitis following EUS-guided CPB was 51 to 59 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. One of the largest studies looking at EUS-guided CPB for chronic pancreatitis pain included 90 patients. That study found a significant improvement in overall pain scores in 55 percent of patients at four and eight weeks of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/25\">",
"     25",
"    </a>",
"    ]. A persistent benefit beyond 12 and 24 weeks was observed in 26 and 10 percent of patients, respectively. Pain relief was more likely in older patients (&gt;45) and those who had not had previous surgery for chronic pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EUS METHODS FOR DIRECT CELIAC \"GANGLIA\" NEUROLYSIS AND BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recognition that celiac ganglia can be visualized and accessed by EUS permits direct injection into individual celiac ganglia to perform celiac ganglia neurolysis (CGN) and celiac ganglia block (CGB) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Celiac ganglia detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The celiac ganglia are typically located to the left of the celiac artery, anterior to the aorta and are predominantly oval or almond shaped, with irregular margins, ranging in size from 2x3 mm to 7x20 mm (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70232 \" href=\"UTD.htm?9/63/10225\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/28\">",
"     28",
"    </a>",
"    ]. In comparison with the surrounding retroperitoneal fat, the ganglia are echo-poor and often display similar echogenicity to that of the left adrenal gland. Central echo-rich strands or foci are present, and echo-poor threads can be seen arising from ganglia. These threads connect to the ganglia, or course along the anterior surface of the celiac trunk. Color Doppler ultrasonography confirms little or no flow within these structures. A review of the CT images of patients with visualized celiac ganglia demonstrated comma-shaped structures between the celiac artery and left adrenal gland corresponding to the ganglia visualized by EUS.",
"   </p>",
"   <p>",
"    In contrast to lymph node fine-needle aspiration (FNA), aspiration of ganglia typically induces transient pain during the FNA and the corresponding cytologic examination displays nerve cell bodies in the absence of lymphocytes (",
"    <a class=\"graphic graphic_picture graphicRef54517 \" href=\"UTD.htm?14/41/14996\">",
"     picture 1",
"    </a>",
"    ). EUS trucut biopsy specimens have also been performed, again inducing transient pain with corresponding histology and revealing nerve cells in the absence of lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was initially unclear how often ganglia could be visualized by EUS and whether the presence of pathological factors (eg, inflammation or malignancy) was necessary for their visualization. We evaluated 200 consecutive nonselected patients and documented ganglia visualization in 81 percent of patients overall [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/27\">",
"     27",
"    </a>",
"    ]. The rate of ganglia detection varied based upon the instrument used (radial EUS 79 percent versus linear EUS 86 percent) and among endosonographers (65 to 97 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/27\">",
"     27",
"    </a>",
"    ]. Patient age, alcohol consumption, cigarette use, body mass index, or the presence of chronic abdominal pain or malignancy had no bearing on the identification or number of ganglia identified.",
"   </p>",
"   <p>",
"    The high rate of ganglion visualization and the lack of correlation with other pathologic processes suggested that factors such as edema, fibrosis, inflammation, and malignancy were unnecessary for the visualization of ganglia. Similar conclusions were reached in a later study involving 57 consecutive patients using radial echoendoscopy in which the ganglia were detected in 89 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/38\">",
"     38",
"    </a>",
"    ]. The ganglia were also identified by CT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;All aspects of the procedure including patient candidacy, sedation, antibiotic use, and follow-up are identical to that of standard",
"    <span class=\"nowrap\">",
"     CPN/CPB",
"    </span>",
"    except for a few technical aspects detailed below. Our general approach is to target as many ganglia as possible (",
"    <a class=\"graphic graphic_figure graphicRef76500 \" href=\"UTD.htm?30/54/31586\">",
"     figure 2",
"    </a>",
"    ). We position the needle tip within the central point of ganglia smaller than 1.0 cm within the axis of the needle plane. For ganglia 1.0 cm or larger in the needle plane axis, we typically advanced the needle tip to the deepest point within the ganglia and injected as the needle is slowly withdrawn.",
"   </p>",
"   <p>",
"    Direct injection commonly results in enlargement of the ganglia (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58737 \" href=\"UTD.htm?16/6/16483\">",
"     image 5",
"    </a>",
"    ). Intraganglia injection is typically accompanied by the immediate onset of pain, which manifests as an abrupt increase in patient movement, attempted verbalization, altered pulse and respiration including patients undergoing anesthesia-assisted sedation. These manifestations resolve abruptly within a few seconds after ganglia injection. The potential significance of pain with injection is described further below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Efficacy for pancreatic cancer pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients reported pain relief in 16 of 17 patients (94 percent) when alcohol was injected and 0 of 1 (0 percent; p = 0.004) with steroid injection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/39\">",
"     39",
"    </a>",
"    ]. For those who reported pain relief, 16 patients had partial relief and none experienced complete pain relief. Narcotic use increased in two patients, remained equivalent in 13 patients, and decreased in three patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Efficacy for chronic pancreatitis pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the direct injection approach has the potential to enhance efficacy and safety. An initial report included 33 patients who underwent 36 procedures for unresectable pancreatic cancer (CGN n = 17, CGB n = 1) or chronic pancreatitis (CGN n = 5, CGB n = 13) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/39\">",
"     39",
"    </a>",
"    ]. Injection included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    (0.25 percent) and alcohol (99 percent) for CGN, or bupivacaine (0.25 percent) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (DepoMedrol, (80 mg per 2cc) for CGB) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/39\">",
"     39",
"    </a>",
"    ]. Ganglia could be seen and accessed in 33 of 35 patients (95 percent). In two patients, the ganglia could not be identified (n = 1) or were diminutive (n = 1) and standard techniques were used.",
"   </p>",
"   <p>",
"    In patients with chronic pancreatitis, four of five patients (80 percent) who received alcohol reported pain relief versus 5 of 13 (38 percent; p = 0.11) who received steroids. When pain relief occurred, the benefit was rated as complete or partial in four and five patients, respectively. Use of narcotics increased, remained equivalent, and decreased in 0, 15, and 3 patients, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Significance of initial pain exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the study described above, patients were categorized as having \"immediate\" pain when discomfort was observed while the needle was within the ganglia, which was distinguished from \"initial\" pain exacerbation, which began in the recovery room or soon thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/39\">",
"     39",
"    </a>",
"    ]. Thirteen (36 percent) patients (CGN, n = 7; CGB, n = 6) experienced an \"initial\" pain exacerbation lasting a mean of 2.2 days for CGN and 1.1 days for CGB. Hospitalization was required in three patients (CGN [n = 1, one day], CGB [n = 2, one and two days]), and another patient who underwent CGB was evaluated in the emergency department and treated with opioid analgesics without hospitalization.",
"   </p>",
"   <p>",
"    Initial pain exacerbation predicted enhanced pain relief at follow-up. For pancreatic cancer, seven of seven patients (100 percent) who had an initial pain exacerbation reported eventual efficacy of CGN versus 9 of 11 who did not have pain (81 percent; p = 0.23). For patients with chronic pancreatitis, 5 of 6 (83 percent) versus 4 of 12 (33 percent; p = 0.05) had subsequent pain relief depending on whether they did or did not experience an initial exacerbation of their pain. For the group as a whole, eventual pain relief was more often reported in patients who developed initial pain compared with those who did not (12 of 13 (92 percent) versus 13 of 23 (57 percent; p&lt;0.03), respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147380561\">",
"    <span class=\"h1\">",
"     OTHER APPLICATIONS OF EUS-GUIDED NEUROLYSIS AND NERVE BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are lacking on the use of EUS-guided celiac plexus and ganglia interventions for other indications.",
"   </p>",
"   <p>",
"    EUS-guided neurolysis and nerve block have been studied for the treatment of chronic pelvic pain. In a pilot study of five patients with pelvic pain due to cancer, EUS-guided injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    and alcohol in to the superior hypogastric plexus resulted in a mean reduction in pain scores from 9 to 3 after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/40\">",
"     40",
"    </a>",
"    ]. The pain relief persisted from 2 to 16 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, serious complications with CPN or CPB are uncommon. As an example, in a series of 189 EUS-guided CPBs and 31 CPNs, four complications were observed (overall complication rate of 1.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/41\">",
"     41",
"    </a>",
"    ]. Three occurred after CPB (1.6 percent) and one after CPN (3.2 percent). The complications included asymptomatic hypotension (CPN), retroperitoneal abscess (CPB) and severe self-limited postprocedural pain in two patients (CPB).",
"   </p>",
"   <p>",
"    Transient diarrhea and hypotension are common manifestations of the sympathetic blockade that can occur following CPN or CPB and may be seen in up to 38 and 44 percent of patients, respectively, whether performed by EUS or percutaneous approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/16\">",
"     16",
"    </a>",
"    ]. The celiac plexus is a dense network of abdominal visceral afferent nerve fibers and sympathetic fibers of the splanchnic nerves. Thus, interruption of the plexus with an alcohol injection not only reduces pain transmission from the abdominal organs (pancreas, liver, stomach, kidney, small bowel, and colon) but can also result in a sympathetic blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/9\">",
"     9",
"    </a>",
"    ]. Clinical manifestations of sympathetic blockade can include diarrhea and hypotension due to a relative unopposed visceral parasympathetic activity. In addition, cephalic spread of the neurolytic agent may result in involvement of the cardiac nerves and plexus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the report of direct ganglia injection described above, transient hypotension defined by a decrease in blood pressure greater than 20 mmHg systolic or 10 mmHg diastolic occurring within three minutes of upright tilt developed in 12 patients (33 percent), two of whom required additional fluid administration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/39\">",
"     39",
"    </a>",
"    ]. For CGB, diarrhea was reported in two patients (11 percent) lasting one and two weeks. Four patients (22 percent) with pancreatic cancer subjectively noted marked (n = 2) and mild (n = 2) improvement of their narcotic induced constipation. No other complications were reported.",
"   </p>",
"   <p>",
"    In our series of 58 patients who underwent EUS CPN for pancreatic cancer pain, self-limiting diarrhea lasting less than 48 hours occurred in 9 percent of patients and one patient had persistent symptoms that lasted for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/31\">",
"     31",
"    </a>",
"    ]. Transient hypotension reflected by a fall in the blood pressure by 10 to 15 percent was observed in approximately 20 percent of cases. All episodes responded to infusion of intravenous fluids and no patient experienced a sustained episode of hypotension. Transient abdominal pain lasting less than 48 hours was noted in 9 percent of patients.",
"   </p>",
"   <p>",
"    Infectious complications of EUS CPN are uncommon. In a series of 90 patients, only one developed an infectious complication (a peripancreatic abscess), which resolved with a two-week course of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/25\">",
"     25",
"    </a>",
"    ]. The authors speculated that there may have been a predisposition to infection because the patient was taking a proton pump inhibitor at the time of the procedure and may have had gastroduodenal colonization with bacteria. As a result, they suggested that prophylactic antibiotics should be considered in patients who are receiving acid suppression when a steroid agent is used for the CPB. The bactericidal nature of ethanol (used in patients with malignancy) appears to minimize this risk for infection and we do not routinely use antibiotics in this setting irrespective of concurrent usage of antacid agents.",
"   </p>",
"   <p>",
"    Major complications from percutaneous CPN are rare, occurring in approximately 1 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/18\">",
"     18",
"    </a>",
"    ]. These include lower extremity weakness and paresthesias, paraplegia, pneumothorax, renal puncture, and prolonged gastroparesis or diarrhea. Neurologic complications related to CPN are most commonly associated with the posterior approach and appear to occur as a consequence of ischemia of the spinal cord or injection directly into the spinal cord or somatic nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/43\">",
"     43",
"    </a>",
"    ]. However, paraplegia has also been reported with intraoperative celiac plexus block [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/44\">",
"     44",
"    </a>",
"    ]. Ischemia of the spinal cord may result from thrombosis or spasm of the artery of Adamkiewicz, which is located on the left of the spine between T8 and L4 and perfuses the lower two-thirds of the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. The anterior approach may decrease the incidence of neurologic complications since the needle does not traverse the perispinal region or somatic nerves [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/39\">",
"     39",
"    </a>",
"    ]. A fatality related to gastric and aortic necrosis following CPN has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with inoperable pancreatic cancer and abdominal pain requiring opioid analgesics are potential candidates for CPN. The timing of the block relative to pain onset appears to be an important predictor of pain response in patients with pancreatic cancer. In one study, CPN was more effective when the block was performed early after pain onset rather than late in its course [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30088/abstract/7\">",
"     7",
"    </a>",
"    ]. Early pancreatic cancer pain appears to derive mainly from the celiac plexus, while pain during the terminal stages of disease may also involve other visceral and somatic nerves. Thus, CPN performed soon after the onset of pain from pancreatic cancer may increase the rate of response.",
"   </p>",
"   <p>",
"    Selection of patients with pain related to chronic pancreatitis for CPN is less clear. Patients with pain refractory to high doses of opiates may be appropriate candidates although the response may be minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      EUS CPN appears to be as safe and effective as other methods for performing CPN.",
"     </li>",
"     <li>",
"      EUS CPN may be the most cost-effective of all CPN techniques since tumors can be staged and biopsied at the time of CPN.",
"     </li>",
"     <li>",
"      Pain relief lasting for up to 24 weeks has been observed in approximately 70 percent of patients. Initial studies also suggest that EUS CPB may also have a role in the treatment of pain related to chronic pancreatitis. However, its role is still being defined and randomized controlled studies as have been performed for pancreas cancer are lacking.",
"     </li>",
"     <li>",
"      Initial data suggest that in patients with moderate to severe pain secondary to pancreatic cancer or chronic pancreatitis, direct celiac ganglia injection is safe and effective in initial pain management. Prospective, controlled and comparative trials are needed to confirm the safety and assess the long-term efficacy of this approach to pain management compared with conventional techniques. Until then, this approach cannot be recommended for routine practice.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/1\">",
"      Ventafridda GV, Caraceni AT, Sbanotto AM, et al. Pain treatment in cancer of the pancreas. Eur J Surg Oncol 1990; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/2\">",
"      Lankisch PG. Natural course of chronic pancreatitis. Pancreatology 2001; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/3\">",
"      Ventafridda V, Tamburini M, Caraceni A, et al. A validation study of the WHO method for cancer pain relief. Cancer 1987; 59:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/4\">",
"      Yeager MP, Colacchio TA, Yu CT, et al. Morphine inhibits spontaneous and cytokine-enhanced natural killer cell cytotoxicity in volunteers. Anesthesiology 1995; 83:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/5\">",
"      Warshaw AL, Banks PA, Fern&aacute;ndez-Del Castillo C. AGA technical review: treatment of pain in chronic pancreatitis. Gastroenterology 1998; 115:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/6\">",
"      Ward EM, Rorie DK, Nauss LA, Bahn RC. The celiac ganglia in man: normal anatomic variations. Anesth Analg 1979; 58:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/7\">",
"      Ischia S, Ischia A, Polati E, Finco G. Three posterior percutaneous celiac plexus block techniques. A prospective, randomized study in 61 patients with pancreatic cancer pain. Anesthesiology 1992; 76:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/8\">",
"      Brown DL, Moore DC. The use of neurolytic celiac plexus block for pancreatic cancer: anatomy and technique. J Pain Symptom Manage 1988; 3:206.",
"     </a>",
"    </li>",
"    <li>",
"     Plancarte R, Velasquez R, Patt R. Neurolytic blocks of the sympathetic axis. In: Pain, Lippincott, Philadelphia 1993. p.377.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/10\">",
"      Nagakawa T, Mori K, Nakano T, et al. Perineural invasion of carcinoma of the pancreas and biliary tract. Br J Surg 1993; 80:619.",
"     </a>",
"    </li>",
"    <li>",
"     Gebhardt GF. Visceral pain mechanisms. In: Current and emerging issues in cancer pain, Chapman CR, Foley KM (Eds), Raven Press, New York 1993. p.99.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/12\">",
"      Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am J Gastroenterol 2007; 102:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/13\">",
"      Wang PJ, Shang MY, Qian Z, et al. CT-guided percutaneous neurolytic celiac plexus block technique. Abdom Imaging 2006; 31:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/14\">",
"      Carroll I. Celiac plexus block for visceral pain. Curr Pain Headache Rep 2006; 10:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/15\">",
"      Kappis M. Erfahrungen mit local anasthesie bie bauchoperationen. Vehr Dtsch Gesellsch Chir 1914; 43:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/16\">",
"      Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995; 80:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/17\">",
"      Arcidiacono PG, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 2011; :CD007519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/18\">",
"      Lillemoe KD, Cameron JL, Kaufman HS, et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993; 217:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/19\">",
"      Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004; 291:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/20\">",
"      Polati E, Finco G, Gottin L, et al. Prospective randomized double-blind trial of neurolytic coeliac plexus block in patients with pancreatic cancer. Br J Surg 1998; 85:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/21\">",
"      Kawamata M, Ishitani K, Ishikawa K, et al. Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain. Pain 1996; 64:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/22\">",
"      Allen PJ, Chou J, Janakos M, et al. Prospective evaluation of laparoscopic celiac plexus block in patients with unresectable pancreatic adenocarcinoma. Ann Surg Oncol 2011; 18:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/23\">",
"      Sahai AV, Lemelin V, Lam E, Paquin SC. Central vs. bilateral endoscopic ultrasound-guided celiac plexus block or neurolysis: a comparative study of short-term effectiveness. Am J Gastroenterol 2009; 104:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/24\">",
"      Gress F, Schmitt C, Sherman S, et al. A prospective randomized comparison of endoscopic ultrasound- and computed tomography-guided celiac plexus block for managing chronic pancreatitis pain. Am J Gastroenterol 1999; 94:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/25\">",
"      Gress F, Schmitt C, Sherman S, et al. Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: a prospective single center experience. Am J Gastroenterol 2001; 96:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/26\">",
"      Wiersema MJ, Wong GY, Croghan GA. Endoscopic technique with ultrasound imaging for neurolytic celiac plexus block. Reg Anesth Pain Med 2001; 26:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/27\">",
"      Gleeson FC, Levy MJ, Papachristou GI, et al. Frequency of visualization of presumed celiac ganglia by endoscopic ultrasound. Endoscopy 2007; 39:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/28\">",
"      Levy M, Rajan E, Keeney G, et al. Neural ganglia visualized by endoscopic ultrasound. Am J Gastroenterol 2006; 101:1787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/29\">",
"      Wiersema MJ, Wiersema LM. Endosonography-guided celiac plexus neurolysis. Gastrointest Endosc 1996; 44:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/30\">",
"      Sakamoto H, Kitano M, Kamata K, et al. EUS-guided broad plexus neurolysis over the superior mesenteric artery using a 25-gauge needle. Am J Gastroenterol 2010; 105:2599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/31\">",
"      Gunaratnam NT, Sarma AV, Norton ID, Wiersema MJ. A prospective study of EUS-guided celiac plexus neurolysis for pancreatic cancer pain. Gastrointest Endosc 2001; 54:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/32\">",
"      Puli SR, Reddy JB, Bechtold ML, et al. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review. Dig Dis Sci 2009; 54:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/33\">",
"      Kaufman M, Singh G, Das S, et al. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. J Clin Gastroenterol 2010; 44:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/34\">",
"      Wyse JM, Carone M, Paquin SC, et al. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol 2011; 29:3541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/35\">",
"      Iwata K, Yasuda I, Enya M, et al. Predictive factors for pain relief after endoscopic ultrasound-guided celiac plexus neurolysis. Dig Endosc 2011; 23:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/36\">",
"      Levy MJ, Topazian M, Keeney G, et al. Preoperative diagnosis of extrapancreatic neural invasion in pancreatic cancer. Clin Gastroenterol Hepatol 2006; 4:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/37\">",
"      Gerke H, Silva RG Jr, Shamoun D, et al. EUS characteristics of celiac ganglia with cytologic and histologic confirmation. Gastrointest Endosc 2006; 64:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/38\">",
"      Ha TI, Kim GH, Kang DH, et al. Detection of celiac ganglia with radial scanning endoscopic ultrasonography. Korean J Intern Med 2008; 23:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/39\">",
"      Levy MJ, Topazian MD, Wiersema MJ, et al. Initial evaluation of the efficacy and safety of endoscopic ultrasound-guided direct Ganglia neurolysis and block. Am J Gastroenterol 2008; 103:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/40\">",
"      Ayub K. Endoscopic ultrasound-guided superior hypogastric plexus neurolysis: A new technique for the management of pelvic pain. Gastrointest Endosc 2001; 56:S143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/41\">",
"      O'Toole TM, Schmulewitz N. Complication rates of EUS-guided celiac plexus blockade and neurolysis: results of a large case series. Endoscopy 2009; 41:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/42\">",
"      Hardy PA, Wells JC. Coeliac plexus block and cephalic spread of injectate. Ann R Coll Surg Engl 1989; 71:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/43\">",
"      Mercadante S, Nicosia F. Celiac plexus block: a reappraisal. Reg Anesth Pain Med 1998; 23:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/44\">",
"      Hayakawa J, Kobayashi O, Murayama H. Paraplegia after intraoperative celiac plexus block. Anesth Analg 1997; 84:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/45\">",
"      De Conno F, Caraceni A, Aldrighetti L, et al. Paraplegia following coeliac plexus block. Pain 1993; 55:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/46\">",
"      van Dongen RT, Crul BJ. Paraplegia following coeliac plexus block. Anaesthesia 1991; 46:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30088/abstract/47\">",
"      Loeve US, Mortensen MB. Lethal necrosis and perforation of the stomach and the aorta after multiple EUS-guided celiac plexus neurolysis procedures in a patient with chronic pancreatitis. Gastrointest Endosc 2013; 77:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5659 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30088=[""].join("\n");
var outline_f29_24_30088=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NON-EUS METHODS (FOR CELIAC \"PLEXUS\" NEUROLYSIS AND BLOCK)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Efficacy for pancreatic cancer pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Efficacy for chronic pancreatitis pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EUS METHODS (FOR PERFORMING CELIAC \"PLEXUS\" NEUROLYSIS AND BLOCK)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Efficacy for pancreatic cancer pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Efficacy for chronic pancreatitis pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EUS METHODS FOR DIRECT CELIAC \"GANGLIA\" NEUROLYSIS AND BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Celiac ganglia detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Efficacy for pancreatic cancer pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Efficacy for chronic pancreatitis pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Significance of initial pain exacerbation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H147380561\">",
"      OTHER APPLICATIONS OF EUS-GUIDED NEUROLYSIS AND NERVE BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5659\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5659|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/30/4576\" title=\"diagnostic image 1\">",
"      Linear EUS normal anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/8/28801\" title=\"diagnostic image 2\">",
"      EUS needle insertion CPN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/44/20163\" title=\"diagnostic image 3\">",
"      EUS hyperechoic cloud",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/63/10225\" title=\"diagnostic image 4\">",
"      Linear EUS celiac ganglia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/6/16483\" title=\"diagnostic image 5\">",
"      EUS celiac ganglion inject",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5659|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/28/31170\" title=\"figure 1\">",
"      Celiac plexus intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/54/31586\" title=\"figure 2\">",
"      Celiac ganglia intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5659|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/41/14996\" title=\"picture 1\">",
"      Celiac ganglion aspirate",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30935?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17735?source=related_link\">",
"      Exocrine pancreatic cancer: Palliation of symptoms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_24_30089="Insulin therapy in type 2 diabetes mellitus";
var content_f29_24_30089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Insulin therapy in type 2 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30089/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30089/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30089/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/24/30089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of glycemic control in minimizing complications related to diabetes has been well established in type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Similarly, the United Kingdom Prospective Diabetes Study (UKPDS) demonstrated that strict glycemic control in patients with type 2 diabetes results in a similar reduction in risk of microvascular disease (although the impact on prevention of macrovascular complications in type 2 diabetes remains uncertain) (",
"    <a class=\"graphic graphic_figure graphicRef52273 \" href=\"UTD.htm?36/32/37389\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=see_link\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon the results of the UKPDS, normoglycemia is now the goal for many patients with type 2 diabetes. However, target A1C levels in patients with type 2 diabetes should be tailored to the individual, balancing the improvement in microvascular complications with the risk of hypoglycemia. The A1C goal should also be set somewhat higher for older patients and those with a limited life expectancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link&amp;anchor=H19#H19\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\", section on 'Glycemic targets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial therapy should begin with diet, weight reduction, and exercise, which may induce normoglycemia if compliance is optimal.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    therapy (in the absence of contraindications) may be initiated, concurrent with lifestyle intervention, at the time of diabetes diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\", section on 'Medications for initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral agents become less effective as beta cell function declines. The therapeutic options for patients who fail initial therapy with lifestyle intervention and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    are to add a second oral or injectable agent, including insulin, or to switch to insulin. There is no consensus on which option is most effective. However, insulin is the preferred second-line medication for patients with A1C &gt;8.5 percent or with symptoms of hyperglycemia despite metformin titration. Thus, many patients with type 2 diabetes will ultimately require treatment with insulin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Treatment options'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of insulin in achieving optimal glycemic control in patients with type 2 diabetes will be reviewed here. General principles of insulin therapy and insulin therapy in type 1 diabetes are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An interactive case that highlights initiating insulin therapy in type 2 diabetes is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2210?source=see_link\">",
"     \"Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL PATTERNS OF INSULIN SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin is secreted in a pulsatile manner; pulses occur under basal (unstimulated) conditions and in response to meals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/4\">",
"     4",
"    </a>",
"    ]. Basal insulin secretion represents approximately 50 percent of 24-hour insulin production, with the remainder accounted for by prandial (mealtime) excursions.",
"   </p>",
"   <p>",
"    The term \"intensive insulin therapy\" has been used to describe complex regimens that separate basal insulin delivery (given as one to two daily injections of intermediate or long-acting insulin) with superimposed doses of short or rapid-acting insulins three or more times daily. While intensive regimens were initially used for patients with type 1 diabetes, they are used for patients with type 2 diabetes as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INSULIN PREPARATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In type 2 diabetes, insulin is generally provided in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a basal supplement with an intermediate to long-acting preparation (NPH, neutral protamine lispro [NPL], glargine, detemir, or degludec) to suppress hepatic glucose production and maintain near normoglycemia in the fasting state.",
"     </li>",
"     <li>",
"      As a premeal (prandial) bolus dose of short-acting (regular) or rapid-acting (lispro, aspart, glulisine) insulin to cover the extra requirements after food is absorbed. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H3#H3\">",
"       \"General principles of insulin therapy in diabetes mellitus\", section on 'Insulin preparations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approximate time of onset, peak activity, and duration of action of the most commonly used insulins are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For many patients with type 2 diabetes, a basal supplement is often adequate for good glycemic control as endogenous insulin secretion will control the post-prandial excursions. Some patients with type 2 diabetes will require additional premeal boluses, similar to treatment for type 1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H9#H9\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Rapid-acting insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Premixed insulin preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most premixed (biphasic) preparations contain an",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10359?source=see_link\">",
"     intermediate acting insulin",
"    </a>",
"    and either a short or a rapid-acting insulin. Some patients who require premeal insulin in addition to basal insulin prefer premixed insulins for convenience. Some premixed (biphasic) insulin preparations are commercially available, but patients may also draw up their premeal and basal insulins (except for glargine and detemir, which cannot be mixed with rapid-acting insulin) in the same syringe prior to injection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H8#H8\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'Premixed insulins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Premixed preparations offer little glycemic advantage compared with adequately titrated basal and bolus insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In a meta-analysis of trials comparing",
"    <span class=\"nowrap\">",
"     rapid-acting/intermediate",
"    </span>",
"    premixed insulin preparations with other treatments (premixed",
"    <span class=\"nowrap\">",
"     regular/NPH",
"    </span>",
"    insulin, long-acting insulin, and non-insulin agents), premixed rapid-acting preparations were similarly effective in reducing A1C levels as premixed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/7\">",
"     7",
"    </a>",
"    ]. They were more effective in reducing A1C levels than long-acting insulin and oral agents (pooled differences of -0.4 and -0.5 percent, respectively). However, in many of the trials included in the meta-analysis, the dose of insulin or oral agent in the control group was not aggressively titrated to achieve optimal glycemic control.",
"   </p>",
"   <p>",
"    Compared with other insulin therapy (long-acting or",
"    <span class=\"nowrap\">",
"     regular/NPH",
"    </span>",
"    mix), premixed rapid-acting insulin preparations were more effective in reducing postprandial blood glucose levels but less effective in reducing fasting blood glucose. Premixed rapid-acting preparations were more often associated with minor hypoglycemia and weight gain than long-acting insulin or oral agents.",
"   </p>",
"   <p>",
"    Premixed insulin preparations are sometimes used in type 2 diabetics, but we almost never use them in patients with type 1 diabetes. For patients with type 2 diabetes who require prandial insulin, the goal is to adjust the dose of fast-acting insulin immediately prior to a meal and, therefore, we prefer to keep basal and premeal insulin injections separate and adjust them independently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     COMBINATION ORAL AGENT AND INSULIN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent hyperglycemia despite oral hypoglycemic therapy may add insulin to oral medication or may stop the oral drug(s) and begin insulin. The rationale for combination oral hypoglycemic drug and insulin therapy is that, by suppressing hepatic glucose production, the patient can retain the convenience of oral agents, while minimizing total insulin requirements and therefore the degree of hyperinsulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many studies have shown that glycemia improves with insulin combination therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. In some studies, target A1C goals (&le;7 percent) were achieved in 60 to 70 percent of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The efficacy of combination oral and insulin therapy is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link&amp;anchor=H13#H13\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Combination oral and insulin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Choice of insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;When insulin is combined with oral agents, a basal (long- or intermediate-acting) rather than a short-acting premeal (prandial) insulin is a reasonable first choice. However, there is some debate as to which insulin is more effective in improving glucose control and diabetes outcomes. The addition of basal insulin will improve nocturnal and fasting blood sugar, whereas premeal bolus insulin will decrease postprandial glucose excursions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Basal insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;While intermediate-acting NPH insulin has been used commonly at bedtime to supplement oral hypoglycemic drug therapy, longer acting insulins, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    (once daily) and detemir (once or twice daily), added to oral agents are equally effective for reducing A1C values and may cause less nocturnal hypoglycemia, albeit at greater cost [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/9-18\">",
"     9-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to NPH, the time-action profile for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    has virtually no peak (",
"    <a class=\"graphic graphic_figure graphicRef67242 \" href=\"UTD.htm?12/57/13214\">",
"     figure 2",
"    </a>",
"    ), which makes it an acceptable basal insulin preparation for intensive insulin therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     Insulin detemir",
"    </a>",
"    is another available long-acting insulin analog; a fatty acid side chain that allows albumin binding results in prolongation in action [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/19\">",
"     19",
"    </a>",
"    ]. However, its duration of action appears to be substantially shorter than that of insulin glargine (",
"    <a class=\"graphic graphic_table graphicRef73676 \" href=\"UTD.htm?1/62/2028\">",
"     table 1",
"    </a>",
"    ). As an example, in a 52-week study of supplementation of oral therapy with insulin glargine or detemir, there were similar improvements in glycemic control (mean A1C 7.1 and 7.2 percent, respectively), but over half of the participants (55 percent) required twice daily dosing with detemir, as opposed to once daily dosing with glargine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Meta-analyses of trials in patients with type 2 diabetes comparing once-daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    or detemir to once- or twice-daily NPH insulin report similar glycemic control between groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. However, the rates of symptomatic overall and nocturnal hypoglycemia, while relatively infrequent with either basal insulin, were lower in patients treated with either insulin glargine or detemir compared with NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. Thus, insulin glargine and detemir may have some relatively modest clinical advantages over NPH (less symptomatic and nocturnal hypoglycemia) with the important disadvantage of high cost. In addition, some patients in our experience get less than 24-hour coverage and require twice daily therapy.",
"   </p>",
"   <p>",
"    Another intermediate-acting insulin, neutral protamine lispro (NPL), is available in some countries. It has been shown to similarly reduce A1C compared with glargine, and preliminary data suggest that there was no difference in reported episodes of hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/25\">",
"     25",
"    </a>",
"    ]. However, additional studies are required.",
"   </p>",
"   <p>",
"    Another longer-acting basal insulin, insulin degludec, is available in some countries. It is not available in the United States, owing to concern regarding a potential increase in cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/26\">",
"     26",
"    </a>",
"    ]. It is almost identical to human insulin, except for deletion of the last amino acid from the B-chain and the addition of a glutamyl link from LysB29 to a hexadecanedioic fatty acid [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/27\">",
"     27",
"    </a>",
"    ]. This feature allows it to form soluble multihexamers at the injection site, from which monomers slowly separate and are absorbed. This property confers a long duration of action (&gt;40 hours), reduces variability in plasma concentration with once daily dosing, and may permit dosing intervals of more than 24 hours. It appears to have similar glycemic efficacy as that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    , as illustrated by the findings of a one year, open-label, non-inferiority trial comparing insulin glargine with insulin degludec (both administered once daily) in 1030 patients with type 2 diabetes treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/28\">",
"     28",
"    </a>",
"    ]. The reduction in A1C (1.19 versus 1.06 percent) and rates of overall confirmed hypoglycemic episodes were similar in the two groups. The rate of nocturnal hypoglycemic episodes was significantly lower with insulin degludec (0.25 versus 0.39). However, the overall rate of nocturnal hypoglycemia was low in both groups, and the difference is of uncertain clinical significance. The long-term safety profile of insulin degludec is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If once daily insulin is added to oral hypoglycemic therapy in patients with type 2 diabetes, a single daily dose of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10359?source=see_link\">",
"     insulin NPH",
"    </a>",
"    , or detemir given at bedtime or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    given in the morning or at bedtime is a reasonable initial regimen. If nocturnal hypoglycemia or symptomatic hypoglycemia occurs in patients taking bedtime NPH, we adjust the dose or switch to insulin glargine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Premeal (prandial) bolus insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with type 2 diabetes, a basal supplement is often adequate for good glycemic control, but for others, premeal (prandial or preprandial) boluses are necessary as they are in type 1 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H9#H9\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Rapid-acting insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The newer rapid-acting insulins may have a minor glycemic advantage over short-acting (regular) insulin in patients with type 1 diabetes, but they do not have a clinically significant advantage in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This was illustrated in a meta-analysis of 5 randomized, controlled trials (involving 2028 patients with type 2 diabetes) that compared rapid-acting insulin analogues to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    as premeal bolus doses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/29\">",
"     29",
"    </a>",
"    ]. No significant differences were seen in serum A1C concentrations or the number of hypoglycemic episodes. However, the ability to inject the rapid-acting insulins immediately before meals, as opposed to the 30 to 45 minutes before the meal recommended for short-acting insulins, may provide improved convenience for patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link&amp;anchor=H9#H9\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\", section on 'Rapid-acting insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are also several trials in patients with type 2 diabetes comparing inhaled insulin to subcutaneous rapid-acting insulin, which report similar improvements in A1C in the inhaled and subcutaneous insulin groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, in these studies, neither the inhaled insulin nor the control arms achieved optimal glycemic efficacy that has been achieved with injection regimens in previous trials with insulin. An inhaled form of rapid-acting insulin was available for a short time but was discontinued in 2007. Other inhaled insulin preparations are in clinical trials but are not currently available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Comparison of insulin regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of randomized trials have evaluated different insulin regimens in patients with type 2 diabetes, almost all of whom were also treated with oral agents. These trials primarily used glycemic control as the endpoint; data are more limited on cardiovascular outcomes. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Conclusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Basal versus prandial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both basal and prandial regimens are similarly effective in reducing A1C concentrations when insulin doses are aggressively titrated to achieve glycemic goals. This was illustrated by a randomized trial of once daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    versus prandial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/48/17160?source=see_link\">",
"     insulin lispro",
"    </a>",
"    in 415 patients who were inadequately controlled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and a sulfonylurea [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/33\">",
"     33",
"    </a>",
"    ]. There were similar improvements in A1C (mean decrease of 1.7 and 1.9 percent, respectively) and target A1C concentrations between 6.5 and 7.0 percent were achieved by 27 and 30 percent of subjects, respectively. Basal insulin was associated with greater patient satisfaction and less hypoglycemia.",
"   </p>",
"   <p>",
"    Similar findings were noted in the HEART2D trial, which was designed to evaluate the effects of prandial (lispro) or basal (NPH twice daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    once daily) insulin on cardiovascular outcomes in 1115 patients after myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/34\">",
"     34",
"    </a>",
"    ]. At baseline, 50 percent of the patients were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , sulfonylureas, or both, whereas the remaining patients were treated with insulin monotherapy.",
"   </p>",
"   <p>",
"    At a mean follow-up of 2.7 years, the trial was stopped early due to lack of efficacy. There was no difference between the prandial and basal groups in both A1C (7.7 versus 7.8 percent) and the time to a subsequent cardiovascular event (cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for an acute coronary syndrome).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Basal or prandial versus premixed",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, premixed insulin regimens with fixed combinations of short or rapid acting insulin with long or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10359?source=see_link\">",
"     intermediate acting insulin",
"    </a>",
"    claim to provide two peaks of insulin activity from just one injection, although in practice the peaks from the rapid acting and intermediate acting insulins tend to merge together and form a single peak of insulin action. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Premixed insulin preparations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Compared with oral agent-basal insulin regimens, oral agent-premixed regimens provide similar or better glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In contrast, in a trial comparing a combined oral agent-basal insulin regimen with premixed insulin without oral agents, the oral agent-basal regimen was more effective in reducing A1C [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/37\">",
"     37",
"    </a>",
"    ]. Relatively few patients in these trials achieved target A1C levels, possibly related to inadequate titration of insulin in all groups. In addition, the premixed regimens were associated with more frequent mild hypoglycemic events.",
"   </p>",
"   <p>",
"    In a three-year trial, 708 patients with type 2 diabetes who were suboptimally controlled with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and a sulfonylurea were randomly assigned to premixed biphasic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/42/10920?source=see_link\">",
"     insulin aspart",
"    </a>",
"    (twice daily), prandial insulin aspart (three times daily), or basal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/49/25367?source=see_link\">",
"     insulin detemir",
"    </a>",
"    (once or twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/38\">",
"     38",
"    </a>",
"    ]. There was no difference in median A1C levels among the three groups (7.1, 6.8, and 6.9 percent, respectively), but significantly more patients in the basal and prandial groups achieved an A1C level of &le;6.5 percent than in the biphasic premixed group (43, 45, and 32 percent, respectively). The majority of all three treatment groups used a second type of insulin, per protocol, during the trial to obtain the stipulated glycemic goals. Patients in the basal group had the fewest episodes of hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Conclusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether a basal or a prandial (premeal) bolus strategy is more effective in improving important diabetes endpoints (microvascular and macrovascular complications) remains uncertain. In the absence of such data, we prefer initiating basal insulin, rather than prandial insulin, in patients who are poorly controlled on oral agents (",
"    <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"UTD.htm?19/63/20467\">",
"     algorithm 1",
"    </a>",
"    ). For patients who require prandial insulin, we prefer to keep basal and prandial insulin injections",
"    <strong>",
"     separate",
"    </strong>",
"    and adjust them independently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\", section on 'Insulin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link&amp;anchor=H9#H9\">",
"     \"General principles of insulin therapy in diabetes mellitus\", section on 'ADA guidelines for mixed-insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Insulin dose",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Basal",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a bedtime dose of NPH, detemir, or glargine insulin is being added to oral hypoglycemic drug therapy, we recommend starting at 10 units or 0.2 units per kg (taken at 10:00 PM if the person is testing his or her fasting blood glucose at 7:00 AM or 8:00 AM). Fasting blood glucose (FBG) should be measured every day. An increase of 2 to 4 units in the bedtime insulin dose should be made periodically (approximately every three days) if the mean FBG is above 130",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    during this time (",
"    <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"UTD.htm?19/63/20467\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/39\">",
"     39",
"    </a>",
"    ]. In this way, the bedtime insulin dose can be titrated over a period of several weeks or months. If fasting glucose levels are very elevated (&gt;250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [13.9",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    or if a patient is known to be very insulin resistant, initial doses can be higher and titration more aggressive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Bolus",
"    </span>",
"    &nbsp;&mdash;&nbsp;If premeal bolus insulin needs to be added, the optimal dose depends upon many factors, including current and target blood glucose values, carbohydrate content of the meal, and activity. A typical starting dose is approximately 4 to 6 units (",
"    <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"UTD.htm?19/63/20467\">",
"     algorithm 1",
"    </a>",
"    ). The dose can be increased by 2 to 3 units every three days until the postprandial blood glucose target is achieved.",
"   </p>",
"   <p>",
"    A more complex method for adjusting premeal insulin is to match insulin delivery to the anticipated glucose excursion with meals. With this approach (called carbohydrate counting), insulin-to-carbohydrate ratios are determined based upon an individual's usual insulin requirements and carbohydrate intake. A dose is then calculated that will control post-prandial blood glucose excursions. Insulin to carbohydrate ratios can vary with the time of day, and are affected by stress, illness, and variations in physical activity. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link&amp;anchor=H9#H9\">",
"     \"Nutritional considerations in type 1 diabetes mellitus\", section on 'Advanced carbohydrate counting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients require specific training in carbohydrate counting, which requires some arithmetical computations that some patients find difficult or burdensome. Furthermore, it is uncertain if there is a glycemic advantage of carbohydrate counting in patients with type 2 diabetes. As an example, in a 24-week randomized trial in 277 adults with type 2 diabetes, there was no difference in A1C values when mealtime insulin adjustments were based upon a simple algorithm (according to previous weeks blood glucose monitoring results) or carbohydrate counting, using an insulin-to-carbohydrate ratio for each meal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/40\">",
"     40",
"    </a>",
"    ]. Thus, either method is acceptable, and patient preference can guide the choice of method for premeal dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Optimal timing of insulin dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with type 2 diabetes on combination therapy (oral hypoglycemics and once-daily insulin), the optimal timing of the insulin dose depends in part upon the type of insulin. NPH insulin may be most effective if given at bedtime [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The advantages of bedtime NPH administration were best illustrated in a trial of 153 patients with type 2 diabetes receiving oral hypoglycemic therapy who were randomly assigned to oral therapy alone or oral therapy plus one of four NPH insulin regimens (single morning dose, single bedtime dose, or one of two multiple injection regimens combining NPH and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/41\">",
"     41",
"    </a>",
"    ]. Glycemic control was similar in all of the insulin groups, and better than the oral therapy-only group. However, the group receiving bedtime NPH had less weight gain and hyperinsulinism than the other insulin groups. Thus, patients with type 2 diabetes on oral hypoglycemic therapy did not do better with multiple insulin injections and bedtime insulin appeared to be preferable to morning administration.",
"   </p>",
"   <p>",
"    In contrast, a morning rather than a bedtime dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    may provide better glycemic control in patients with type 2 diabetes who are also treated with an oral agent. This issue was addressed in a randomized, controlled trial of 695 patients with type 2 diabetes previously treated with oral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/15\">",
"     15",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8823?source=see_link\">",
"       Glimepiride",
"      </a>",
"      given with a morning dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"       insulin glargine",
"      </a>",
"      lowered A1C significantly more than a bedtime dose of NPH (-1.24 versus -0.84 percentage points; difference of 0.40 percent) or a bedtime dose of insulin glargine (-1.24 versus -0.96 percentage points, difference of 0.28 percent).",
"     </li>",
"     <li>",
"      Nocturnal hypoglycemia was less frequent with morning and bedtime",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"       insulin glargine",
"      </a>",
"      than with bedtime NPH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, for patients with type 2 diabetes taking an oral hypoglycemic agent, the optimal timing is once-daily NPH or detemir at bedtime or once-daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    in the morning or bedtime.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SWITCHING TO INSULIN MONOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent hyperglycemia despite oral hypoglycemic therapy may stop the oral drug and begin insulin monotherapy. This approach is cheaper than combined therapy (although generic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    is relatively inexpensive), but results in more weight gain and more episodes of hypoglycemia, few of which are severe. It is not clear if the weight gain is clinically important as microvascular complications were reduced with insulin monotherapy in the UKPDS despite weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"     \"Glycemic control and vascular complications in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2210?source=see_link\">",
"     \"Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Starting dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of insulin in patients with type 2 diabetes switching to monotherapy is similar to the starting dose described above for patients adding insulin to oral hypoglycemic therapy (",
"    <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"UTD.htm?19/63/20467\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients who are taking insulin and have A1C values above the desired target, diet and exercise patterns should first be reviewed. Insulin doses should then be adjusted to achieve target levels of glycemia. Patients should measure blood glucose two to four times daily and should only reduce their insulin dose if hypoglycemia develops. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"     \"Blood glucose self-monitoring in management of adults with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, dietary indiscretion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inadequate doses of insulin underlie the apparent failure of many patients treated with insulin regimens. Daily insulin doses typically exceed 65 to 100 units per day, and may sometimes be much higher, before obese type 2 diabetic patients can achieve near-normal glycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Once-daily regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients receiving insulin monotherapy, a once-daily dose of intermediate- or long-acting insulin is sometimes sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/43\">",
"     43",
"    </a>",
"    ]. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    is effective when used alone for once-daily therapy in patients with type 2 diabetes and may be associated with less nocturnal hypoglycemia and less weight gain than NPH [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Basal insulin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    However, serum insulin concentrations over a 24-hour period may be more stable in patients taking two doses daily, when the insulin preparation is NPH or detemir [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/14,20,44\">",
"     14,20,44",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Basal insulin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Twice-daily regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the goal is control of persistent hyperglycemia with a regimen that is simple, then twice-daily NPH insulin will be effective in many patients. If excessive postprandial rises in blood glucose are a concern, then a short- or rapid-acting insulin must be added. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Insulin dose'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Injection of regular plus NPH insulin before breakfast and before dinner results in four peaks of insulin action, covering the morning, afternoon, evening, and overnight (",
"    <a class=\"graphic graphic_figure graphicRef59453 \" href=\"UTD.htm?9/2/9262\">",
"     figure 3",
"    </a>",
"    ). However, the peaks tend to merge. Furthermore, with the common practice of drawing up both insulin preparations in the same syringe, serum insulin peaks become less distinct. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Premixed insulin preparations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intensive insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of an intensive insulin regimen (similar to that used in type 1 diabetes) results in higher serum insulin concentrations and better glycemic control than that achieved with either an oral drug or conventional insulin therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/45\">",
"     45",
"    </a>",
"    ]. A potential problem is the weight gain (averaging 8.7 kg in one study) that can occur with intensive regimens that achieve near normal glycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/8\">",
"     8",
"    </a>",
"    ]. This weight gain may in some instances result in partial noncompliance with therapy, particularly in women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link\">",
"     \"Nutritional considerations in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If intensive insulin therapy is chosen in a patient with type 2 diabetes, the pretreatment considerations, choice of regimen, and management issues are similar to those for patients with type 1 diabetes. These issues are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     INSULIN AS INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative that may be beneficial, but is not widely used, is a brief period (two to four weeks) of intensive insulin treatment at the onset of type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. By inducing near normoglycemia with intensive insulin therapy, both endogenous insulin secretion and insulin sensitivity improve [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/46,48,49\">",
"     46,48,49",
"    </a>",
"    ]. The improvement in insulin secretion is presumably due to the elimination of the deleterious effects of hyperglycemia on beta cell secretory function, and in some patients, it results in better glycemic control that can then be maintained with diet and exercise for many months thereafter.",
"   </p>",
"   <p>",
"    This was illustrated in a randomized trial of short-term (two to five weeks) intensive insulin therapy versus oral agents (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/42/34470?source=see_link\">",
"     gliclazide",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    ) in 410 Chinese patients with newly diagnosed type 2 diabetes (mean fasting glucose 202",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [11.2",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/50\">",
"     50",
"    </a>",
"    ]. Insulin and oral agents were titrated to achieve a fasting glucose of &lt;110",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.1",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    Therapy was discontinued two weeks after meeting goal glucose. The patients were instructed to continue diet and exercise only and were closely followed for recurrence of hyperglycemia (fasting glucose &gt;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [7.0",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    or postprandial glucose &gt;180",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [10.0",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    Patients who failed to achieve the glycemic target within two weeks (n = 23) or could not tolerate oral agents (n = 7) were excluded from the efficacy analysis.",
"   </p>",
"   <p>",
"    A greater proportion of patients receiving insulin achieved glycemic goals in less time than those assigned to oral agents (over 90 percent within 4.0 to 5.6 days versus 84 percent in 9.3 days). Remission rates after one year were higher in the insulin groups (insulin pump or multiple daily injections) than in the oral hypoglycemic group (51 and 45 versus 27 percent). Patients in remission had lower initial fasting glucose and A1C, and achieved glycemic goals more quickly than those with recurrent hyperglycemia. Thus, insulin can be considered as initial therapy for all patients with type 2 diabetes, and can result in remission for one year or longer.",
"   </p>",
"   <p>",
"    A separate issue related to initial insulin versus oral hypoglycemic therapy is the severity of the baseline metabolic disturbance. Insulin should be particularly considered for patients presenting with A1C &gt;10 percent, fasting plasma glucose &gt;250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (13.9",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    random glucose consistently &gt;300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (16.7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    ketonuria, or with unplanned weight loss in association with hyperglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adult-onset type 1 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential problem is that patients who are initially thought to have type 2 diabetes may actually have type 1 diabetes and therefore require insulin as initial therapy. Although the peak incidence of type 1 diabetes occurs around the time of puberty, approximately 25 percent of cases present after 35 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/51\">",
"     51",
"    </a>",
"    ]. There are certain clinical features that, if present at any age, suggest the diagnosis of type 1 diabetes. These include marked and otherwise unexplained recent weight loss (irrespective of the initial weight), a short history with severe symptoms, and the presence of moderate to heavy ketonuria. Diabetic ketoacidosis at first presentation suggests that the patient has type 1 diabetes and will require lifelong insulin treatment, although there are exceptions to this general rule [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some individuals with adult-onset type 1 diabetes may slowly progress to insulin dependence and at presentation may be indistinguishable from a patient with type 2 diabetes. This is sometimes referred to as \"latent autoimmune diabetes in adults\" (LADA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link&amp;anchor=H6#H6\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\", section on 'Distinguishing type 1 from type 2 diabetes'",
"    </a>",
"    .) LADA can be distinguished from type 2 diabetes by the presence of pancreatic autoantibodies, such as glutamic acid decarboxylase antibodies. These individuals are likely to respond poorly to oral hypoglycemic drug therapy, and the use of sulfonylureas as initial therapy may cause earlier insulin dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30089/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The best initial treatment strategy for LADA is unclear. Studies are required to determine whether early treatment with insulin or use of immunomodulator therapy may prevent disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=see_link\">",
"       \"Patient information: Using insulin (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial therapy in most patients with type 2 diabetes should begin with diet, weight reduction, exercise, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    therapy (in the absence of contraindications), which may induce normoglycemia if compliance is optimal. After a successful initial response to oral therapy, most patients fail over time (",
"    <a class=\"graphic graphic_figure graphicRef81706 \" href=\"UTD.htm?17/5/17502\">",
"     figure 4",
"    </a>",
"    ) and require additional therapy (add a second oral or injectable agent, including insulin, or switch to insulin). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=see_link\">",
"     \"Initial management of blood glucose in type 2 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"     \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If once per day insulin is added to oral hypoglycemic therapy in patients with type 2 diabetes, either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10359?source=see_link\">",
"       insulin NPH",
"      </a>",
"      or detemir given at bedtime or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"       insulin glargine",
"      </a>",
"      given in the morning or at bedtime is a reasonable initial regimen (",
"      <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"UTD.htm?19/63/20467\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Optimal timing of insulin dose'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2210?source=see_link\">",
"       \"Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When switching to insulin monotherapy, it is reasonable to begin with a similar regimen consisting of basal insulin (NPH, detemir, or glargine insulin) given once or twice daily (",
"      <a class=\"graphic graphic_algorithm graphicRef73793 \" href=\"UTD.htm?19/63/20467\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Starting dose'",
"      </a>",
"      above.) Subsequent modifications can be made according to blood glucose and A1C values.",
"     </li>",
"     <li>",
"      Insulin can be considered initial therapy for all patients with type 2 diabetes, particularly patients presenting with A1C &gt;10 percent, fasting plasma glucose &gt;250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (13.9",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      random glucose consistently &gt;300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (16.7",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      or ketonuria.",
"     </li>",
"     <li>",
"      A potential problem is that patients who are initially thought to have type 2 diabetes may actually have type 1 diabetes and therefore require insulin as initial therapy. In patients in whom it is difficult to distinguish type 1 from type 2 diabetes (patients who are underweight, are losing weight, or are ketotic), initial treatment with insulin is required. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Insulin as initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although we do not recommend premixed insulin for the treatment of type 1 diabetes, it is a reasonable option for patients with type 2 diabetes who are doing well on a stable, fixed ratio. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Premixed insulin preparations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"       \"General principles of insulin therapy in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      More complex insulin regimens can be used in patients with type 2 diabetes in an attempt to achieve near normoglycemia by adding short- or rapid-acting insulin before meals. The principles of intensive insulin regimens are the same for type 1 and type 2 diabetics and are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"       \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/1\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/2\">",
"      Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353:2643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/3\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/4\">",
"      Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/5\">",
"      Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008; 31:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/6\">",
"      Hirao K, Arai K, Yamauchi M, et al. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Pract 2008; 79:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/7\">",
"      Qayyum R, Bolen S, Maruthur N, et al. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008; 149:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/8\">",
"      Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial. Diabetes Care 1993; 16:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/9\">",
"      Yki-J&auml;rvinen H, Kauppinen-M&auml;kelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/10\">",
"      Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/11\">",
"      Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006; 29:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/12\">",
"      Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26:3080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/13\">",
"      Yki-J&auml;rvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/14\">",
"      Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/15\">",
"      Fritsche A, Schweitzer MA, H&auml;ring HU, 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/16\">",
"      Hirsch IB. Insulin analogues. N Engl J Med 2005; 352:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/17\">",
"      Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/18\">",
"      Gale EA. Newer insulins in type 2 diabetes. BMJ 2012; 345:e4611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/19\">",
"      Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 2004; 21:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/20\">",
"      Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008; 51:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/21\">",
"      Rosenstock J, Dailey G, Massi-Benedetti M, et al. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/22\">",
"      Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; :CD005613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/23\">",
"      Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/24\">",
"      Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008; 81:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/25\">",
"      Esposito K, Ciotola M, Maiorino MI, et al. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. Ann Intern Med 2008; 149:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/26\">",
"      Torjesen I. FDA raises concerns about ultra-long acting insulins given green light in Europe and Japan. BMJ 2012; 345:e7323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/27\">",
"      Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012; 29:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/28\">",
"      Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012; 35:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/29\">",
"      Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006; :CD003287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/30\">",
"      Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab 2009; 11:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/31\">",
"      Hermansen K, R&ouml;nnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004; 27:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/32\">",
"      Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/33\">",
"      Bretzel RG, Nuber U, Landgraf W, et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/34\">",
"      Raz I, Wilson PW, Strojek K, et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009; 32:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/35\">",
"      Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/36\">",
"      Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007; 357:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/37\">",
"      Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc 2007; 55:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/38\">",
"      Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/39\">",
"      Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/40\">",
"      Bergenstal RM, Johnson M, Powers MA, et al. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care 2008; 31:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/41\">",
"      Yki-J&auml;rvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/42\">",
"      Puhakainen I, Taskinen MR, Yki-J&auml;rvinen H. Comparison of acute daytime and nocturnal insulinization on diurnal glucose homeostasis in NIDDM. Diabetes Care 1994; 17:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/43\">",
"      Cusi K, Cunningham GR, Comstock JP. Safety and efficacy of normalizing fasting glucose with bedtime NPH insulin alone in NIDDM. Diabetes Care 1995; 18:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/44\">",
"      Taylor R, Davies R, Fox C, et al. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study. Diabetes Care 2000; 23:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/45\">",
"      United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995; 310:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/46\">",
"      Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 27:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/47\">",
"      Ilkova H, Glaser B, Tun&ccedil;kale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/48\">",
"      Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27:2597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/49\">",
"      Garvey WT, Olefsky JM, Griffin J, et al. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 1985; 34:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/50\">",
"      Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371:1753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/51\">",
"      Leslie RD, Elliott RB. Early environmental events as a cause of IDDM. Evidence and implications. Diabetes 1994; 43:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/52\">",
"      Umpierrez GE, Casals MM, Gebhart SP, et al. Diabetic ketoacidosis in obese African-Americans. Diabetes 1995; 44:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/53\">",
"      Maruyama T, Tanaka S, Shimada A, et al. Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus. J Clin Endocrinol Metab 2008; 93:2115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30089/abstract/54\">",
"      Brophy S, Davies H, Mannan S, et al. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 2011; :CD006165.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1801 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30089=[""].join("\n");
var outline_f29_24_30089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL PATTERNS OF INSULIN SECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INSULIN PREPARATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Premixed insulin preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      COMBINATION ORAL AGENT AND INSULIN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Choice of insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Basal insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Premeal (prandial) bolus insulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Comparison of insulin regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Basal versus prandial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Basal or prandial versus premixed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Conclusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Insulin dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Basal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Bolus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Optimal timing of insulin dose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SWITCHING TO INSULIN MONOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Starting dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Once-daily regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Twice-daily regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intensive insulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      INSULIN AS INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adult-onset type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1801\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1801|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?19/63/20467\" title=\"algorithm 1\">",
"      Insulin titration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1801|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/32/37389\" title=\"figure 1\">",
"      Microvascular endpoint and control",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/57/13214\" title=\"figure 2\">",
"      Insulin glargine versus NPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/2/9262\" title=\"figure 3\">",
"      Time course of insulin action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/5/17502\" title=\"figure 4\">",
"      HbA1c with intensive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1801|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/62/2028\" title=\"table 1\">",
"      Insulin pharmacokinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=related_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=related_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/35/43577?source=related_link\">",
"      Initial management of blood glucose in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/10/2210?source=related_link\">",
"      Interactive diabetes case 2: Switching from oral agents to insulin in type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=related_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=related_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=related_link\">",
"      Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/58/28579?source=related_link\">",
"      Patient information: Using insulin (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_24_30090="Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes";
var content_f29_24_30090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30090/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30090/contributors\">",
"     Florence Roufosse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30090/contributors\">",
"     Amy D Klion, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30090/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30090/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/24/30090/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30090/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/24/30090/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/24/30090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypereosinophilic syndromes (HES) are a group of disorders marked by the sustained overproduction of eosinophils, in which eosinophilic infiltration and mediator release cause damage to multiple organs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Although these disorders had long been considered idiopathic (eg, as in the &ldquo;idiopathic hypereosinophilic syndrome,&rdquo; IHES), etiologies for some forms of HES have now been described.",
"   </p>",
"   <p>",
"    The clinical features, pathophysiology, and diagnosis of HES will be reviewed here. The treatment of these disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25898?source=see_link\">",
"     \"Treatment of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definition of HES, originally presented in 1975 and",
"    <strong>",
"     subsequently modified as noted below",
"    </strong>",
"    , proposed three defining features [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood eosinophilia of",
"      <span class=\"nowrap\">",
"       &ge;1500/microliter,",
"      </span>",
"      present for more than six months",
"     </li>",
"     <li>",
"      No other apparent etiologies for eosinophilia, such as parasitic infection or allergic disease",
"     </li>",
"     <li>",
"      Signs",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptoms of eosinophil-mediated end-organ dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these criteria have been helpful historically in regrouping patients sharing risks of eosinophil-induced organ damage in the setting of unexplained hypereosinophilia, they have a number of limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some HES patients require therapeutic interventions well before the six-month period specified in the first criterion, in order to treat or prevent potentially disabling or life-threatening complications of sustained hypereosinophilia.",
"     </li>",
"     <li>",
"      New diagnostic approaches have led to the identification of distinct molecular or immunological mechanisms underlying eosinophil expansion in some patient subgroups. This subset of patients would have been excluded by the second criterion, as would patients with relatively common allergic diseases, even though the level of eosinophilia might suggest another coexistent disorder. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The third criterion excludes patients with early HES, who have not yet developed signs and symptoms of disease, as well as a largely unstudied group of patients with clinically benign eosinophilia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To address these limitations, the evolving definition of HES integrates diseases in which eosinophils play a central role in pathogenesis, while taking pathogenic heterogeneity into consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/3\">",
"     3",
"    </a>",
"    ]. This new wider definition encompasses HES variants with well-characterized pathogenic mechanisms, truly idiopathic HES, familial HES, organ-specific eosinophil-mediated disease, and benign HES. Although the lower limit of 1.5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    (or",
"    <span class=\"nowrap\">",
"     1500/microliter)",
"    </span>",
"    is retained in the modern definition of HES, the six-month duration criterion is no longer applied because exclusion of secondary causes of hypereosinophilia takes less time than it used to, and there is no reason to withhold treatment in a patient with sustained and potentially deleterious hypereosinophilia once underlying diseases have been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19581555\">",
"    <span class=\"h2\">",
"     Expert consensus terminology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A panel of experts reached consensus on terminology pertaining to hypereosinophilic conditions and published recommendations in 2012 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Hypereosinophilia (HE) is defined as blood eosinophils &gt;1.5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    on two examinations separated in time by at least one month",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue HE.",
"   </p>",
"   <p>",
"    Tissue HE is defined by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On bone marrow section, a percentage of eosinophils that exceeds 20 percent of all nucleated cells,",
"      <span class=\"nowrap\">",
"       <strong>",
"        and/or",
"       </strong>",
"      </span>",
"     </li>",
"     <li>",
"      Tissue infiltration that is extensive in the opinion of a pathologist,",
"      <span class=\"nowrap\">",
"       <strong>",
"        and/or",
"       </strong>",
"      </span>",
"     </li>",
"     <li>",
"      Marked deposition of eosinophil granule proteins in tissue (in the absence or presence of major tissue infiltration by eosinophils)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19581596\">",
"    <span class=\"h3\">",
"     Hypereosinophilic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;A hypereosinophilic syndrome (HES) is defined by the association of hypereosinophilia (as defined above), with eosinophil-mediated organ damage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysfunction, provided other potential causes for the damage have been excluded.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term hypereosinophilic syndrome can therefore be used to qualify any disease characterized by eosinophilic infiltrates and associated complications,",
"      <strong>",
"       including situations where the cause of hypereosinophilia is identified",
"      </strong>",
"      (eg, restrictive cardiac disease occurring in the setting of parasitic infections [L&ouml;ffler&rsquo;s endocarditis]).",
"     </li>",
"     <li>",
"      In contrast, the term hypereosinophilic syndrome should",
"      <strong>",
"       not",
"      </strong>",
"      be used when the clinical manifestations and underlying organ damage found in a hypereosinophilic patient can be explained by a mechanism other than hypereosinophilia. As an example, a patient with cardiovascular risk factors presenting with persistent hypereosinophilia and thoracic pain, which is shown to be secondary to coronary artery occlusion, should not be diagnosed as hypereosinophilic syndrome, unless another clinical manifestation can be attributed to eosinophilic tissue infiltration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hypereosinophilic syndromes are further subclassified according to the pathogenic mechanisms resulting in eosinophil expansion: primary, secondary, or idiopathic.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Primary (or neoplastic) HES",
"      </strong>",
"      : In primary HES, eosinophilic expansion occurs in the setting of an underlying stem cell, myeloid, or eosinophilic neoplasm, and is considered (or proven) clonal.",
"     </li>",
"     <li>",
"      <strong>",
"       Secondary (or reactive) HES",
"      </strong>",
"      : In secondary HES, eosinophilic expansion is driven by overproduction of eosinophilopoietic cytokines by other cell types, and is polyclonal. This is typically the situation encountered in parasitic infections, certain solid tumors, and T cell lymphoma, wherein marked secondary hypereosinophilia may be responsible for organ damage and dysfunction. Lymphocytic variant HES is a subvariant in this category. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Diagnosis of L-HES'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Idiopathic HES",
"      </strong>",
"      : In idiopathic HES, the underlying cause of hypereosinophilia remains unknown despite thorough etiological work-up. The associated organ damage generally warrants therapeutic intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to hypereosinophilic syndromes, several other clinical situations associated with hypereosinophilia can be defined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific syndromes associated with hypereosinophilia, in which the contribution of eosinophils to the clinical presentation and disease complications remains unknown (eg, Churg-Strauss syndrome, Gleich&rsquo;s syndrome).",
"     </li>",
"     <li>",
"      Organ restricted inflammatory conditions associated with hypereosinophilia, in which the effect of eosinophils remains unclear.",
"     </li>",
"     <li>",
"      &ldquo;Hypereosinophilia of undetermined significance,&rdquo; which describes patients with persistent unexplained hypereosinophilia, but without apparent complications related to tissue eosinophilia. This terminology highlights both the lack of an explanation for hypereosinophilia, and the inability to predict whether the patient will eventually develop clinical manifestations related to eosinophilic organ infiltration, and thus progress to hypereosinophilic syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HES is rare and the true prevalence unknown. In one study that used clinician coding of eosinophilia to identify patients with HES in the Surveillance, Epidemiology and End Results (SEER) database, the estimated prevalence was between 0.36 to 6.3 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients are diagnosed between the ages of 20 and 50 years, although HES (including, rarely, myeloproliferative variants) can develop in children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1,8,9\">",
"     1,8,9",
"    </a>",
"    ]. When HES is suspected in a child, a careful evaluation for clonal abnormalities should be performed, as preliminary evidence suggests that these may be found in a higher percentage of children, compared with adults [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Certain variants of HES (ie, those associated with aberrations in the gene for tyrosine kinase receptor platelet-derived growth factor receptor alpha (",
"    <em>",
"     PDGFRA",
"    </em>",
"    )) occur almost exclusively in males, whereas others (lymphocytic variant HES and HES of unknown etiology) appear to be equally distributed between the sexes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'HES variants'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophils are derived from myeloid progenitors in the bone marrow, through the action of three hematopoietic cytokines: granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin (IL)-3, and IL-5. Of these three, only IL-5 is specific for eosinophil differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Theories of pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several mechanisms have been proposed to account for the dysregulated overproduction of eosinophils in patients with HES [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clonal eosinophilic proliferation as a result of a primary molecular defect involving hematopoietic stem cells",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      defects in signal transduction from the receptors that mediate eosinophilopoiesis",
"     </li>",
"     <li>",
"      Overproduction of eosinophilopoietic cytokines, such as IL-5",
"     </li>",
"     <li>",
"      Functional abnormalities of the eosinophilopoietic cytokines, related to enhanced or prolonged biologic activity",
"     </li>",
"     <li>",
"      Defects in the normal suppressive regulation of eosinophilopoiesis or of eosinophil survival and activation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the initial description of HES, progress has been made in identifying specific etiologic abnormalities that underlie the hypereosinophilia in some patients. Based upon case series in the literature, a reasonable estimate of the prevalence of a documented molecular or immunologic etiology in HES is 20 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/10,13-16\">",
"     10,13-16",
"    </a>",
"    ]. However, the true proportion of all patients with unexplained hypereosinophilia and identified abnormalities remains unknown, since the techniques used for identification have not been uniformly applied across series. Moreover, it is probable that each of the major investigative groups is affected by referral biases favoring HES patients with certain clinical presentations. Thus, whereas a specific center may observe a particular etiology to be common in their own patients with HES, it remains to be defined how frequently each of these occurs in the broader population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     HES variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;HES has been subdivided into several clinically relevant variants (",
"    <a class=\"graphic graphic_algorithm graphicRef69583 \" href=\"UTD.htm?23/29/24016\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myeloproliferative variants of HES",
"     </li>",
"     <li>",
"      HES T-lymphocytic variants (L-HES)",
"     </li>",
"     <li>",
"      Familial HES",
"     </li>",
"     <li>",
"      Idiopathic HES",
"     </li>",
"     <li>",
"      Overlap HES &mdash; The term &ldquo;overlap&rdquo; is applied to disorders with blood eosinophilia",
"      <span class=\"nowrap\">",
"       &ge;1500/microliter",
"      </span>",
"      in the setting of single organ involvement.",
"     </li>",
"     <li>",
"      Associated HES &mdash; The term &ldquo;associated&rdquo; is applied to disorders with blood eosinophilia",
"      <span class=\"nowrap\">",
"       &ge;1500/microliter",
"      </span>",
"      in association with a distinct second diagnosis, such as ulcerative colitis, in which eosinophilia has been reported, but is not the predominant abnormality driving end-organ manifestations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features and molecular abnormalities of each variant are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef59869 \" href=\"UTD.htm?26/19/26940\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Myeloproliferative HES variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subgroup of patients with HES display features more typical of myeloproliferative disorders, including increased serum vitamin B12 levels, chromosomal abnormalities, anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia, hepatomegaly, splenomegaly, and circulating leukocyte precursors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1,18,19\">",
"     1,18,19",
"    </a>",
"    ]. These patients tend to be more refractory to glucocorticoid therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25898?source=see_link\">",
"     \"Treatment of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12440488\">",
"    <span class=\"h4\">",
"     Myeloproliferative neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some HES patients with myeloproliferative features have responded to treatment with tyrosine kinase inhibitors. Clonal chromosomal aberrations not recognizable by conventional cytogenetics have been demonstrated in the majority of these patients, leading to reclassification of this subset as having myeloproliferative neoplasms (MPN) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Such patients fall into the category",
"    <span class=\"nowrap\">",
"     &ldquo;primary/neoplastic",
"    </span>",
"    hypereosinophilic syndromes&rdquo; in the 2012 consensus classification proposal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2008 WHO classification system of hematopoietic and lymphoid tissues includes a special category for myeloid and lymphoid disorders with eosinophilia and abnormalities in one of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <em>",
"       PDGFRA",
"      </em>",
"      or PDGFRalpha: the gene for tyrosine kinase receptor platelet-derived growth factor receptor alpha",
"     </li>",
"     <li>",
"      <em>",
"       PDGFRB",
"      </em>",
"      or PDGFRbeta: the gene for tyrosine kinase receptor platelet-derived growth factor receptor beta",
"     </li>",
"     <li>",
"      <em>",
"       FGFR1",
"      </em>",
"      , the gene for fibroblast growth factor receptor 1 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such patients may present as or evolve into acute myeloid or lymphoblastic leukemia.",
"   </p>",
"   <p>",
"    The best characterized and most frequently observed chromosomal aberration is an interstitial deletion on chromosome 4q12 resulting in the fusion of two genes, those for Fip1-like1 (",
"    <em>",
"     FIP1L1",
"    </em>",
"    ) and platelet-derived growth factor receptor alpha (",
"    <em>",
"     PDGFRA)",
"    </em>",
"    . The",
"    <em>",
"     FIP1L1",
"    </em>",
"    -",
"    <em>",
"     PDGFRA",
"    </em>",
"    fusion displays constitutive tyrosine kinase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/19,24-27\">",
"     19,24-27",
"    </a>",
"    ]. The prevalence of the FIP1L1-",
"    <em>",
"     PDGFRA",
"    </em>",
"    chromosomal fusion among patients fulfilling HES criteria is estimated to be between 10 and 14 percent, although this is not certain [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/10,13,28\">",
"     10,13,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25898?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of the hypereosinophilic syndromes\", section on 'Other tyrosine kinase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myeloproliferative variants of HES may also be caused by other chromosomal rearrangements, including fusion of",
"    <em>",
"     PDGFRA",
"    </em>",
"    with other partner genes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] or fusions involving",
"    <em>",
"     PDGFRB",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/31\">",
"     31",
"    </a>",
"    ], or point mutations in",
"    <em>",
"     PDGFRA",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/32\">",
"     32",
"    </a>",
"    ]. Rare patients with chronic eosinophilic leukemia, not otherwise specified (CEL-NOS), in which blasts are increased in the bone marrow and criteria are not met for another known lymphoid or myeloid neoplasm, have also been described and have aggressive disease that is typically unresponsive to standard therapies for HES.",
"   </p>",
"   <p>",
"    There have been a limited number of reports documenting clonal populations of mature eosinophils in patients with idiopathic HES [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The markers used relied upon X-linked polymorphisms, limiting these analyses to women. In addition, these tests are not widely available. Patients with clonal populations of eosinophils have had none of the typical myeloproliferative features described previously and have responded to treatment with glucocorticoids alone. This suggests that the mechanisms of eosinophil expansion in this subset of patients are different from those associated with a tyrosine kinase mutation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     T cell lymphocytic variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphocytic variant HES (L-HES) is more insidious in nature, and is characterized by a predominance of skin and soft tissue involvement. In this variant, which is classified as a subvariant of",
"    <span class=\"nowrap\">",
"     secondary/reactive",
"    </span>",
"    hypereosinophilic syndromes, IL-5 producing T cell subsets have been identified in the peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/35\">",
"     35",
"    </a>",
"    ]. The most frequently reported abnormal T cell phenotype in L-HES is CD3 negative CD4 positive. The prevalence of this variant among all patients with HES is not well defined. In one series of 60 patients with idiopathic eosinophilia, 16 were found to have abnormal IL-5 producing T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/14\">",
"     14",
"    </a>",
"    ]. Clinically, this subset of patients often has cutaneous symptoms that dominate the clinical presentation, although other clinical manifestations of HES, including cardiac involvement, can be present. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Skin disease'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H22\">",
"     'Laboratory features'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to IL-5, the abnormal T cells produce other Th2 cytokines such as IL-4 and IL-13, as well as GM-CSF. The effects of these Th2 cytokines on other cells (eg, B cells) account for associated biological features of L-HES. Indeed, B cell stimulation leads to increased IgE synthesis and polyclonal hypergammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Familial HES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant transmission of marked eosinophilia has been reported. In one family, the gene has been mapped to chromosome 5q31-33 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/37\">",
"     37",
"    </a>",
"    ]. Eosinophilia begins at birth and most family members have remained asymptomatic, although progression, with fatal endomyocardial fibrosis, has occurred in a few individuals.",
"   </p>",
"   <p>",
"    Familial forms also exist in several of the single-organ HES variants, including eosinophilic esophagitis and eosinophilic fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/38-40\">",
"     38-40",
"    </a>",
"    ], and do not appear to differ in clinical presentation from the sporadic forms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Idiopathic HES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite careful evaluation and exclusion of known causes of hypereosinophilia, the etiology of eosinophilia in as many as 75 percent of cases of presumed HES remains undefined. The terms \"idiopathic HES\" [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/3\">",
"     3",
"    </a>",
"    ] and \"HES of unknown etiology\" are used to distinguish these patients from those in earlier series, which included patients with now-defined subtypes. Among patients with multisystem organ involvement, some demonstrate features of myeloproliferative disease similar to those encountered in FIP1L1-PDGFRA-positive individuals, whereas others appear to have more of an \"immuno-allergic\" disorder suggesting possible involvement of T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Overlap HES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overlap disorders are disorders with blood eosinophilia &gt;1.5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    in the setting of single organ involvement. Overlap disorders include a wide variety of single organ-restricted eosinophilic disorders, such as eosinophilic gastrointestinal disorders, chronic eosinophilic pneumonia, and Well's syndrome. A number of these eosinophilic disorders can be difficult or impossible to distinguish from idiopathic HES when accompanied by blood eosinophilia &gt;1.5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L.",
"    </span>",
"    Whether to pursue an extensive evaluation for other end-organ involvement remains a matter of clinical judgment and should be dictated by the clinical signs and symptoms, degree of eosinophilia, and response to therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=see_link\">",
"     \"Diseases with eosinophilic involvement of specific organs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4769463\">",
"    <span class=\"h3\">",
"     Gleich's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodic angioedema with eosinophilia is characterized by recurrent episodes of angioedema, urticaria, pruritus, fever, weight gain, elevated serum IgM, and leukocytosis with marked blood eosinophilia. The absence of cardiac damage or other end-organ involvement and the episodic nature of the symptoms are distinguishing features of patients with this condition. A subset of these patients presents with a clonal population of T cells consistent with lymphocytic variant HES, while others may progress over time to nonepisodic idiopathic HES (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=see_link\">",
"     \"Diseases with eosinophilic involvement of specific organs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22506766\">",
"    <span class=\"h4\">",
"     Churg-Strauss syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Churg-Strauss syndrome (CSS) is difficult to categorize, particularly in the absence of documented eosinophilic vasculitis on tissue biopsy.",
"    <strong>",
"    </strong>",
"    The authors prefer to view CSS as an overlap disorder, since it is a disease of one organ (blood vessels), although clinical manifestations can involve the sinuses, lungs, skin, heart, peripheral nerves, and other structures. However, other experts believe it is more appropriately placed in the associated category (",
"    <a class=\"graphic graphic_algorithm graphicRef69583 \" href=\"UTD.htm?23/29/24016\">",
"     algorithm 1",
"    </a>",
"    ). This issue remains an area of debate.",
"   </p>",
"   <p>",
"    In some patients presenting with hypereosinophilia, determining if eosinophilia and organ involvement represents HES or CSS can be difficult clinically. Many patients meet diagnostic criteria for both disorders. This is particularly challenging in the early stages of CSS before the development of vasculitis, and in patients who are ANCA-negative. Moreover, both disorders usually respond initially to glucocorticoids, and while glucocorticoid therapy is beneficial, it may further impede the clinician's ability to distinguish between these two conditions. Therefore, histological assessment for vasculitis is recommended when symptoms suggest small and medium-sized blood vessel damage, as therapeutic strategies to treat end-organ injury differ, especially for the choice of second-line agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=see_link\">",
"     \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Associated HES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilia &gt;1.5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    can be seen at times in a variety of conditions associated with immunodysregulation. Examples include collagen vascular diseases, sarcoid, ulcerative colitis, autoimmune lymphoproliferative syndrome, and HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/41-46\">",
"     41-46",
"    </a>",
"    ]. The etiology of the eosinophilia in such cases is unknown, and its impact on disease complications and clinical manifestations remains elusive, but it appears to correlate with the severity of the underlying condition and, in some cases, with prognosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of sarcoidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19581612\">",
"    <span class=\"h2\">",
"     Hypereosinophilia of undetermined significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent hypereosinophilia of unknown etiology and no apparent organ damage or dysfunction are classified as &ldquo;hypereosinophilia of undetermined significance.&rdquo; Although some patients with asymptomatic hypereosinophilia are likely normal variants, they cannot be differentiated at the present time from patients who will ultimately progress to symptomatic HES.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients may present with various combinations of symptoms and signs of end-organ damage mediated by eosinophils. In many patients, the onset of symptoms is insidious and eosinophilia is detected incidentally. However, in others, the initial manifestations are severe and life-threatening due to the rapid evolution of cardiac or neurologic complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Signs and symptoms at presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective multicenter series of 188 patients reported the frequency of specific symptoms at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/10\">",
"     10",
"    </a>",
"    ]. The following types of signs and symptoms were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dermatologic (eg, rash) - 37 percent",
"     </li>",
"     <li>",
"      Pulmonary (cough and breathlessness) - 25 percent",
"     </li>",
"     <li>",
"      Gastrointestinal - 14 percent",
"     </li>",
"     <li>",
"      Cardiac - 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Six percent of patients presented with incidentally detected and clinically asymptomatic hypereosinophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiac disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic myocarditis is a major cause of morbidity and mortality among patients with HES [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1,5,47,48\">",
"     1,5,47,48",
"    </a>",
"    ].",
"    <em>",
"     PDGFRA",
"    </em>",
"    -associated HES has an increased incidence of incapacitating and potentially lethal cardiac involvement in the absence of therapy.",
"   </p>",
"   <p>",
"    Eosinophil-mediated cardiac damage involves increased numbers of eosinophils in conjunction with other ill-defined stimuli that recruit",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    activate eosinophils within the heart tissues. Extracellular deposition of eosinophil granule proteins and evidence of eosinophil activation are present at sites of myocardial injury [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/48\">",
"     48",
"    </a>",
"    ]. The clinicopathologic changes in cardiac tissue associated with HES appear similar to those seen in other disorders with eosinophilic involvement, including eosinophilic leukemia, GM-CSF administration, drug reactions, and parasitic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1,49\">",
"     1,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of cardiac disease in HES is unpredictable. Some patients with sustained eosinophilia never develop cardiac involvement, and the severity of cardiac injury does not clearly correlate with the degree of peripheral eosinophilia. Cardiac involvement does, however, appear to be more common in patients with the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    fusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eosinophil-mediated heart damage evolves through three stages [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An acute necrotic stage",
"     </li>",
"     <li>",
"      An intermediate phase characterized by thrombus formation along the damaged endocardium",
"     </li>",
"     <li>",
"      A fibrotic stage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with HES often develop cardiopulmonary symptoms and signs during the thrombotic and fibrotic stages.",
"   </p>",
"   <p>",
"    The acute necrotic stage is characterized pathologically by endocardial damage, myocardial infiltration with eosinophils and lymphocytes, eosinophil degranulation, myocardial necrosis, and the formation of sterile microabscesses. The disease is usually clinically silent at this phase; physical examination generally is normal, although conjunctival",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subungual splinter hemorrhages (which probably represent small emboli from the endocardial surface) are sometimes noted. Elevations in serum troponin levels can be sensitive indicators of early and ongoing eosinophil-associated myocardial damage in forms of HES and Churg-Strauss syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/51-53\">",
"     51-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiography can be normal during the acute necrotic stage. Several reports have shown that contrast-enhanced cardiac magnetic resonance imaging (MRI) reliably detects all stages and aspects of eosinophil-mediated heart damage, including the early stage of myocardial eosinophilic inflammation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82429 \" href=\"UTD.htm?17/5/17503\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Endomyocardial biopsy may provide definitive evidence of eosinophil-associated cardiac involvement, but is typically reserved for patients in whom there is uncertainty whether infiltrating eosinophils are causing cardiac disease. Staining of biopsy specimens with antibodies for eosinophil granule proteins, including major basic protein 1 (MBP1), can demonstrate eosinophil-related tissue damage even in the absence of significant eosinophil accumulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The second stage of heart disease involves thrombus formation along areas of damaged endocardium. Symptoms and signs commonly appear at this stage and include dyspnea, chest pain, signs of left",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    right ventricular failure, mitral or tricuspid regurgitation, cardiomegaly, and T wave inversions on the electrocardiogram. Echocardiography and cardiac MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/57\">",
"     57",
"    </a>",
"    ] may demonstrate intracardiac thrombi (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50869 \" href=\"UTD.htm?39/14/40174\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The thrombogenic sequelae of eosinophilic tissue infiltration may arise from the actions of eosinophil peroxidase in forming hypothiocyanous acid, a compound which diffuses into endothelial cells and strongly induces tissue factor expression by these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/58\">",
"     58",
"    </a>",
"    ]. Tissue factor, believed to be crucial in thrombus formation, is also expressed by eosinophils directly [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/59\">",
"     59",
"    </a>",
"    ]. The major complication of intracardiac thrombus formation is the detachment and distant embolization of thrombotic material, leading to embolic strokes, ischemia of extremities, and other embolic events. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Thrombotic complications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=see_link\">",
"     \"Echocardiography in detection of intracardiac sources of embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the third, fibrotic stage, progressive scarring causes endomyocardial fibrosis, producing a restrictive cardiomyopathy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mitral or tricuspid valve regurgitation due to entrapment of the chordae tendineae. Echocardiography and cardiac MRI may show evidence of fibrosis, such as thickening of the posterior mitral valve leaflet or the posterior wall, and increases in endomyocardial echodensity in areas of fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=see_link\">",
"     \"Endomyocardial fibrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neurologic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;HES may be complicated by cerebral thromboemboli, encephalopathy, peripheral neuropathy, or longitudinal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transverse sinus thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/60\">",
"     60",
"    </a>",
"    ]. Neurologic complaints, particularly those associated with cerebral thromboemboli, are occasionally the presenting symptoms of HES.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebral thromboemboli can arise from intracardiac thrombi and manifest as embolic strokes or transient ischemic episodes. MRI imaging can reveal multiple infarcts in watershed border zone distributions [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cardiac disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Encephalopathy can present with behavioral changes, confusion, ataxia, and memory loss. Affected patients may also have signs of upper motor neuron injury, such as increased muscle tone, heightened deep tendon reflexes, and a positive Babinski response. How these changes occur is not known. Encephalopathic changes are more likely with markedly elevated blood leukocyte and eosinophil numbers and may derive from microvascular occlusion.",
"     </li>",
"     <li>",
"      Peripheral neuropathy accounts for approximately one-half of the neurologic manifestations of HES. The neuropathy may be symmetric or asymmetric, involve sensory with or without motor nerves, and may produce mononeuritis multiplex or radiculopathy with denervation muscle atrophy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=see_link\">",
"       \"Differential diagnosis of peripheral nerve and muscle disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pathophysiology of the peripheral neuropathy in patients with HES remains largely unexplained. Biopsies of affected nerves generally show an axonal neuropathy with varying degrees of axonal loss, but no evidence of vasculitis or eosinophilic infiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Thrombotic complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of case reports suggest that venous and arterial blood vessels may be damaged in HES, although the mechanisms remain largely unknown. Patients have been reported to develop femoral artery occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/62\">",
"     62",
"    </a>",
"    ], intracranial sinus thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/63,64\">",
"     63,64",
"    </a>",
"    ], or digital gangrene in the setting of progressive Raynaud's phenomenon.",
"   </p>",
"   <p>",
"    Microvascular thrombosis and occlusion due to eosinophil-related damage to endothelium combined with activation of the coagulation system has been reported in association with acute renal failure and cold-induced Raynaud's phenomenon causing digital necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1,65,66\">",
"     1,65,66",
"    </a>",
"    ]. While eosinophils may impact coagulation pathways at different levels, the precise mechanisms leading to hypercoagulability remain elusive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=see_link\">",
"     \"Pathogenesis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Ocular manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular symptoms, particularly blurred vision, may be related to microemboli or local thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1,67,68\">",
"     1,67,68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Skin disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common skin manifestations of HES include eczema (involving hands, flexural areas, or dispersed plaques), erythroderma, generalized thickening of the skin (lichenification), dermographism, recurrent urticaria, and angioedema [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1,69\">",
"     1,69",
"    </a>",
"    ]. Biopsies of papular or nodular lesions show perivascular infiltration with eosinophils and mild-to-moderate perivascular neutrophilic and mononuclear infiltrates without vasculitis.",
"   </p>",
"   <p>",
"    Less commonly, mucosal ulcers, which are often difficult to treat, develop in the mouth, nose, pharynx, esophagus, and stomach, or on the penis or anus. Biopsy of these ulcers demonstrates a nonspecific mixed cellular infiltrate without eosinophilia, vasculitis, or microthrombi [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1\">",
"     1",
"    </a>",
"    ]. Eosinophil granule deposition may be seen on immunofluorescence staining. Several cases of HES with concomitant lymphomatoid papulosis, a T cell-mediated chronic dermatosis, have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/70\">",
"     70",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=see_link\">",
"     \"Lymphomatoid papulosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence and type of dermatologic lesions may provide valuable prognostic information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      L-HES can present with prominent cutaneous symptoms. In the series mentioned previously, 14 of 16 L-HES patients had cutaneous lesions, including erythroderma, urticaria, and plaques [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/14\">",
"       14",
"      </a>",
"      ]. Patients with cutaneous symptoms should be investigated for the presence of abnormal T cells. Positive cases should be monitored for development of T cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who experienced angioedema and urticaria, with or without other symptoms, were likely to have a benign course without cardiac or neurologic complications, as noted in the previously mentioned series of referred HES subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/67,71\">",
"       67,71",
"      </a>",
"      ]. Some of these patients might have had the syndrome of episodic angioedema and eosinophilia (Gleich&rsquo;s syndrome), which had not yet been recognized. (See",
"      <a class=\"local\" href=\"#H4769463\">",
"       'Gleich's syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with mucosal ulcerations are more likely to have",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"       -positive",
"      </span>",
"      HES.",
"     </li>",
"     <li>",
"      The existence of lymphomatoid papulosis should prompt a search for the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      mutation, as this association has been reported in a small number of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary involvement is common in HES and may result from eosinophilic infiltration of the lung with subsequent fibrosis, heart failure, or pulmonary emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/67\">",
"     67",
"    </a>",
"    ]. In a 2011 retrospective series of 49 patients seen at the Mayo Clinic, respiratory symptoms were reported in 63 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/72\">",
"     72",
"    </a>",
"    ]. The most common presenting symptoms were dyspnea (45 percent), cough (39 percent) and wheezing (24 percent). Abnormal chest radiography or CT findings were seen in 43 percent of patients and included parenchymal infiltrates (37 percent), pleural effusion (14 percent), intrathoracic lymphadenopathy (12 percent) and pulmonary emboli (4 percent). Infiltrates were most commonly patchy ground glass infiltrates. Of note, two of the patients with bilateral parenchymal infiltrates had no respiratory symptoms. Lung biopsy, when performed, revealed eosinophilic infiltrates. Differentiation from other diseases that cause pulmonary infiltrates with eosinophilia is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=see_link\">",
"     \"Causes of pulmonary eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Gastrointestinal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic gastritis, enteritis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colitis may occur secondary to HES and cause weight loss, abdominal pain, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1\">",
"     1",
"    </a>",
"    ]. Hepatic involvement may take the form of chronic active hepatitis, focal hepatic lesions, eosinophilic cholangitis, or the Budd-Chiari syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=see_link\">",
"     \"Etiology of the Budd-Chiari syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     LABORATORY FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, the peripheral blood in HES contains eosinophilia &gt;1.5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef53980 \" href=\"UTD.htm?8/1/8213\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/5\">",
"     5",
"    </a>",
"    ]. Circulating eosinophils are usually mature, although eosinophilic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myeloid precursors may also be present. Total leukocyte counts in excess of 90 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    are associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anemia may be present, especially in patients with the myeloproliferative variants, and either thrombocytopenia or thrombocytosis may be noted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of routine karyotyping are normal in the majority of patients; cytogenetic abnormalities were noted in only 1 of 18 patients in one series and 8 of 33 in another [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/67,74\">",
"     67,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HES should be suspected in patients with persistent eosinophilia &gt;1.5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    in the peripheral blood on at least two occasions in the absence of identifiable causes. An evaluation should be pursued even if the patient is asymptomatic.",
"   </p>",
"   <p>",
"    The initial evaluation of a patient with eosinophilia (ie, elevated but not &gt;1.5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L)",
"    </span>",
"    is presented separately. The specific testing required to rule out other etiologies differs depending upon findings from a thorough history and physical examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Initial studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following initial tests are recommended to assess for end-organ involvement:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood chemistries, including liver enzymes, creatine kinase, renal function, and troponin",
"     </li>",
"     <li>",
"      Electrocardiogram",
"     </li>",
"     <li>",
"      Echocardiogram",
"     </li>",
"     <li>",
"      Pulmonary function tests",
"     </li>",
"     <li>",
"      Chest x-ray and CT",
"     </li>",
"     <li>",
"      Abdominal CT",
"     </li>",
"     <li>",
"      Tissue biopsies and additional studies as clinically indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, several biomarkers are currently under study for their predictive value regarding HES subtypes and should be measured (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Diagnosis of HES subtypes'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum tryptase (most consistently elevated in myeloproliferative variants (M-HES), variable in other subtypes)",
"     </li>",
"     <li>",
"      Serum vitamin B12 (elevated in M-HES)",
"     </li>",
"     <li>",
"      Serum immunoglobulins (particularly IgE) (often elevated in L-HES, variable in M-HES and other subtypes)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hematologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with persistent unexplained hypereosinophilia should undergo further evaluation to identify possible HES subtypes or underlying causes not previously identified.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bone marrow aspiration and biopsy should be obtained and examined for cellularity, increased CD34 expression, and dysplastic changes. Special stains should be included to identify reticulin fibrosis and mast cells. Bone marrow samples should be evaluated with routine karyotyping. While gene fusion events mediating HES are rarely detectable by conventional chromosomal cytogenetics and require specific testing, genetic changes associated with other disorders (eg, chronic myeloid leukemia or CMML with translocations involving",
"      <em>",
"       PDGFRB",
"      </em>",
"      ) may be identified. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Chronic myeloid or myelomonocytic leukemia'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The bone marrow in patients with HES demonstrates increased eosinophils and eosinophil precursors (",
"      <a class=\"graphic graphic_picture graphicRef88547 \" href=\"UTD.htm?32/19/33079\">",
"       picture 2",
"      </a>",
"      ). Patients with increased serum tryptase or atypical mast cells on bone marrow biopsy should also be screened for the 816V c-kit mutation associated with systemic mastocytosis (available at specialty academic centers). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Myeloproliferative HES variants'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"       \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An evaluation for chronic myeloid leukemia is indicated [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/75\">",
"       75",
"      </a>",
"      ]. This may be accomplished by one of the following methods: karyotypic analysis of the bone marrow sample or evaluation of the peripheral blood with either fluorescence in situ hybridization (FISH) for t(9;22) or reverse transcriptase polymerase chain reaction (RT-PCR) for BCR-ABL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link\">",
"       \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Molecular testing for the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      mutation should be performed on peripheral blood",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bone marrow. This is accomplished using FISH techniques for the CHIC2 locus, (which is normally located between the two fusion partners, and is therefore absent in the presence of the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      fusion),",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      RT-PCR techniques for the fusion transcript (commercially available in the United States through Quest Laboratories and Mayo Clinic) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/24,76\">",
"       24,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T lymphocyte phenotyping on peripheral blood by multiparameter flow cytometry, including concomitant staining and analyses for (at a minimum) CD3, CD4, and CD8 (to detect CD3 negative, CD4 positive subsets) should be performed in all cases. T cell receptor rearrangement studies on peripheral blood",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bone marrow (available at specialty academic centers) should be done concomitantly to diagnose lymphocytic variant HES. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'T cell lymphocytic variants'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending upon the clinical presentation and the urgency to initiate therapy, investigations may be performed sequentially, starting with those that appear more likely to be informative. For example, if a patient presents with splenomegaly, mucosal ulcers of the oral cavity, and signs of heart failure, studies aimed at evaluating etiologies of myeloproliferative HES (eg, assays related to the presence of the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    fusion) are indicated. Ideally, diagnostic testing for myeloproliferative or lymphocytic etiologies for HES should be performed expeditiously prior to initiating clinically indicated HES therapies that might suppress cell populations necessary to ascertain etiologies of HES variants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Diagnosis of HES subtypes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Diagnosis of myeloproliferative variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic eosinophilic",
"    <span class=\"nowrap\">",
"     leukemia/myeloproliferative",
"    </span>",
"    variants of HES are characterized by increased serum vitamin B12 levels, an abnormal leukocyte alkaline phosphatase score, chromosomal abnormalities, anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia, elevated serum tryptase, hepatomegaly, splenomegaly, and circulating leukocyte precursors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large, retrospective, multicenter study, very high levels of vitamin B12 (&gt;2000",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      were a marker for the presence of the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      fusion [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the same study, elevations of serum tryptase were more frequent in",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      positive M-HES, compared to patients without the mutation (82 versus 20 percent), and mean values were higher (31 versus 19",
"      <span class=\"nowrap\">",
"       pg/mL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic eosinophilic leukemia (CEL) is the result of an autonomous clonal proliferation of eosinophil precursors. Patients with CEL by definition do not demonstrate the Philadelphia chromosome or",
"    <em>",
"     BCR-ABL",
"    </em>",
"    fusion gene. As in other subtypes of HES, the peripheral blood demonstrates mature eosinophils with only a small number of eosinophilic myelocytes or promyelocytes. There may be a variety of morphologic abnormalities, including sparse granulation, cytoplasmic vacuolization, or",
"    <span class=\"nowrap\">",
"     hyper/hyposegmentation,",
"    </span>",
"    but none of these changes are specific for CEL. The bone marrow contains less than 20 percent blasts. The key criteria for making the diagnosis of CEL are the presence of a clonal cytogenetic or molecular genetic abnormality or blast cells that account for more than 2 or 5 percent of the peripheral blood or bone marrow, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2008 WHO classification system of hematopoietic and lymphoid tissues includes a special category for myeloid and lymphoid disorders with eosinophilia and abnormalities of",
"    <em>",
"     PDGFRA",
"    </em>",
"    ,",
"    <em>",
"     PDGFRB",
"    </em>",
"    , or",
"    <em>",
"     FGFR1",
"    </em>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/21\">",
"     21",
"    </a>",
"    ]. Such a diagnosis is made by the identification of genetic abnormalities in any of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet derived growth factor receptor alpha (eg, the",
"      <span class=\"nowrap\">",
"       <em>",
"        FIP1L1/PDGFRA",
"       </em>",
"      </span>",
"      fusion)",
"     </li>",
"     <li>",
"      Platelet derived growth factor receptor beta (",
"      <em>",
"       PDGFRB",
"      </em>",
"      ) such as t(5;12)(q31-35;p13) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/19\">",
"       19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Fibroblast growth factor receptor 1 (",
"      <em>",
"       FGFR1",
"      </em>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As mentioned above, testing for",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    fusion is available commercially in the United States. Tests for the less common chromosomal fusion events including",
"    <em>",
"     PDGFRB",
"    </em>",
"    and",
"    <em>",
"     FGFR1",
"    </em>",
"    are not commercially available, although routine karyotypes are abnormal in such cases.",
"   </p>",
"   <p>",
"    The presence of an elevated serum tryptase concentration in the setting of myeloproliferative features may help to identify HES patients with the",
"    <em>",
"     FIP1L1-PDGFRA",
"    </em>",
"    fusion gene [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/50\">",
"     50",
"    </a>",
"    ]. HES patients with elevated tryptase levels have increased numbers of mast cells on bone marrow biopsy, similar to patients with systemic mastocytosis (",
"    <a class=\"graphic graphic_picture graphicRef87634 \" href=\"UTD.htm?39/37/40537\">",
"     picture 3",
"    </a>",
"    ). In both conditions, these mast cells may be morphologically abnormal (ie, spindle-shaped).",
"   </p>",
"   <p>",
"    It is important to distinguish",
"    <em>",
"     FIP1L1-PDGFRA",
"    </em>",
"    -positive HES patients from those with systemic mastocytosis and eosinophilia due to a mutation in c-kit, because 816V, the most common c-kit mutation, is resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     imatinib",
"    </a>",
"    , the standard therapy for",
"    <em>",
"     FIP1L1-PDGFRA",
"    </em>",
"    -positive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/13,77\">",
"     13,77",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rare patients with clonal eosinophilia do exist who lack myeloproliferative features. Human androgen receptor analysis (HUMARA) can be used to demonstrate clonal populations of mature eosinophils in these patients. These X-linked analyses can only be performed on females [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Diagnosis of L-HES",
"    </span>",
"    &nbsp;&mdash;&nbsp;HES T-lymphocytic variants (L-HES) are usually insidious in onset and often involve cutaneous signs and symptoms. They are characterized by the following laboratory findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Abnormal surface markers",
"      </strong>",
"      &mdash; Routine analyses, even multiparameter flow cytometry of CD3, CD4, and CD8 expression on lymphocytes, have not been sufficient to detect all phenotypes. Some patients with clonal populations of T cells by PCR do not have detectable phenotypic abnormalities using flow cytometric analysis.",
"      <br/>",
"      <br/>",
"      The most frequently encountered subset is CD3-CD4+, although CD3+CD4-CD8-, CD4+CD7-, and other populations of T cells have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/14,15,36,78-80\">",
"       14,15,36,78-80",
"      </a>",
"      ]. A literature review of published cases of L-HES confirmed that the frequency of cutaneous manifestations was especially high among patients with a CD3-CD4+ T cell subset [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Skin disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       TARC level",
"      </strong>",
"      &mdash; When available, elevations in serum thymus and activation-regulated chemokine (TARC) may also be a helpful marker of L-HES [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/10,81\">",
"       10,81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       T cell clonality",
"      </strong>",
"      &mdash; Clonality of phenotypically aberrant T cells has been demonstrated in many cases through analysis of TCR gene rearrangement patterns. T cell TCR studies should be performed, although demonstration of T cell clonality is not sufficient to define L-HES. Conventional chromosomal karyotypes are generally normal, although rare cases with 16q breakage, partial 6q or 10p deletions, and trisomy 7 have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/80,82\">",
"       80,82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Increased serum IgE and polyclonal hypergammaglobulinemia",
"      </strong>",
"      &mdash; As mentioned previously, the abnormal T cells in this variant produce Th2 cytokines, leading to increased IgE synthesis and polyclonal hypergammaglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/36\">",
"       36",
"      </a>",
"      ]. Serum IgE and gammaglobulin levels should be determined, although increases are neither necessary nor specific for diagnosis of L-HES.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Diagnosis of familial HES",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should be queried about a family history of eosinophilia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endomyocardial fibrosis. However, routine testing of family members is of low yield and should only be performed if there is a suggestive family history or patient concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Diagnosis of overlap and associated forms of HES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fulfill criteria for one of the co-existing conditions associated with eosinophilia, AND have blood eosinophilia of &gt;1.5 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L,",
"    </span>",
"    may be diagnosed with overlap or associated forms of HES. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Overlap HES'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Associated HES'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of conditions can be associated with secondary blood or tissue eosinophilia and clinical manifestations of HES, including leukemias and lymphomas, paraneoplastic syndromes, KIT mutation-associated systemic mastocytosis with eosinophilia, drug hypersensitivity reactions, and helminth infections. These are important to diagnose, as treatment should be directed at the underlying cause rather than the eosinophilia itself. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationships among HES, acute leukemias, chronic eosinophilic leukemias, and myelodysplastic syndromes continue to be refined [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/19,24,77,83,84\">",
"     19,24,77,83,84",
"    </a>",
"    ]. Patients with HES can develop T cell lymphomas or acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/35,77\">",
"     35,77",
"    </a>",
"    ], and patients with acute lymphocytic leukemia (ALL), especially those with pre-B cell ALL, can present clinically with HES, although molecular evidence of a clonal lymphocyte population can usually be detected at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/77,85\">",
"     77,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Acute eosinophilic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute eosinophilic leukemia may be distinguished from other forms of HES by the marked increase in the number of IMMATURE eosinophils in the blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marrow, the finding of greater than 10 percent blast forms in the marrow, infiltration of tissues (including the central nervous system and bones) with immature eosinophil forms, and a clinical course similar to other acute leukemias, with pronounced anemia, thrombocytopenia, and susceptibility to infection. Cardiac and neurologic complications can develop in acute eosinophilic leukemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Chronic myeloid or myelomonocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic myeloid leukemia (CML) or chronic myelomonocytic leukemia (CMML) may demonstrate an absolute eosinophilia, although clinical complications due to the eosinophilia are relatively uncommon. CML can be identified by the detection of",
"    <em>",
"     BCR-ABL",
"    </em>",
"    fusion mRNA, the Bcr-Abl protein, or the Philadelphia chromosome. CMML has characteristics on bone marrow examination and often involves a translocation involving chromosomes 5 and 12, leading to autonomous tyrosine kinase activity of",
"    <em>",
"     PDGFRB",
"    </em>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H64021195#H64021195\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'Chronic myelomonocytic leukemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Systemic mastocytosis with eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic mastocytosis with eosinophilia can be confused with",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"     -associated",
"    </span>",
"    disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/50\">",
"     50",
"    </a>",
"    ]. However, systemic mastocytosis is usually associated with D816V mutations in the KIT gene. Systemic mastocytosis is characterized clinically by approximately equal sex distribution, a characteristic skin rash (urticaria pigmentosa), and prominent gastrointestinal symptoms. In contrast, HES (with the",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    mutation) demonstrates a male predominance and is associated with heart failure and restrictive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aside from mutational analysis, the two disorders are most reliably distinguished by the ratio of absolute eosinophil count to serum total tryptase",
"    <span class=\"nowrap\">",
"     (AEC/tryptase),",
"    </span>",
"    which is &gt;100 in HES with",
"    <span class=\"nowrap\">",
"     <em>",
"      FIP1L1/PDGFRA",
"     </em>",
"    </span>",
"    mutation, and &lt;100 in systemic mastocytosis with eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/24/30090/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypereosinophilic syndromes (HES) are disorders marked by the sustained overproduction of eosinophils, associated with damage to one or more organs due to eosinophilic infiltration and mediator release.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypereosinophilia (HE) is defined as blood &gt;1.5 eosinophils x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      blood on two examinations (at least one month apart)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tissue HE defined by any of the following (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The percentage of eosinophils in a bone marrow section exceeds 20 percent of all nucleated cells,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"     </li>",
"     <li>",
"      A pathologist is of the opinion that tissue infiltration by eosinophils is extensive,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"     </li>",
"     <li>",
"      Marked deposition of eosinophil granule proteins is found (in the absence or presence of major tissue infiltration by eosinophils)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypereosinophilic syndromes are defined as the association of hypereosinophilia as defined above, with eosinophil-mediated organ damage",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dysfunction, in which other potential causes for the damage have been excluded. Hypereosinophilic syndromes may therefore occur in a variety of settings, including in association with well-defined underlying diseases such as parasitic infections. In such cases the eosinophilia and associated complications resolve with treatment of the underlying disease. (See",
"      <a class=\"local\" href=\"#H19581596\">",
"       'Hypereosinophilic syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The HES are most common in patients 20 to 50 years of age. The",
"      <em>",
"       FIP1L1-PDGFRA",
"      </em>",
"      -associated variant affects mostly males, whereas other variants appear to affect males and females in roughly equal proportions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The HES are a heterogeneous group of disorders, encompassing a number of etiologically distinct diseases. Underlying molecular or immunologic defects can be identified in 20 to 30 percent of cases. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Important clinically relevant subtypes include myeloproliferative variants, T cell lymphocytic variants, and familial eosinophilia. These subtypes are associated with a more clearly-defined clinical presentation and prognosis, and, in the case of the",
"      <em>",
"       FIP1L1-PDGFRA",
"      </em>",
"      associated myeloproliferative variant, response to specific therapies. Other complex forms of HES have still-uncertain etiologies, justifying their classification as &ldquo;idiopathic hypereosinophilic syndrome.&rdquo; These represent the bulk of subjects with HES and may be difficult to distinguish from other eosinophil-associated disorders, including Churg-Strauss syndrome. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'HES variants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypereosinophilia of undetermined significance describes patients with persistent unexplained hypereosinophilia, but without apparent complications related to tissue eosinophilia. This terminology highlights both the lack of an explanation for hypereosinophilia, and the inability to predict whether the patient will eventually develop clinical manifestations related to eosinophilic organ infiltration, and thus progress to hypereosinophilic syndrome. (See",
"      <a class=\"local\" href=\"#H19581612\">",
"       'Hypereosinophilia of undetermined significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The organ systems most commonly affected in HES are the heart, skin, lungs, gastrointestinal tract, and nervous system. Patients with HES may present with gradually progressive symptoms, or with life-threatening cardiac and neurologic events, such as thromboembolic stroke or encephalopathy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HES should be considered in patients with sustained blood eosinophilia of &gt;1.5 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L,",
"      </span>",
"      documented on at least two occasions, or evidence of tissue hypereosinophilia. Once secondary causes of eosinophilia that require therapy directed at the underlying cause are excluded (eg, helminth infection, drug hypersensitivity, and neoplastic disease), patients with persistent eosinophilia should be evaluated accordingly, regardless of the presence or absence of symptoms. This evaluation involves an assessment of end-organ involvement as well as specialized studies to identify patients with myeloproliferative or clonal lymphocytic variants. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/1\">",
"      Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/2\">",
"      Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy 2004; 59:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/3\">",
"      Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/4\">",
"      Sheikh J, Weller PF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/5\">",
"      Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/6\">",
"      Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012; 130:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/7\">",
"      Crane MM, Chang CM, Kobayashi MG, Weller PF. Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence. J Allergy Clin Immunol 2010; 126:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/8\">",
"      Farruggia P, D'Angelo P, Acquaviva A, et al. Hypereosinophilic syndrome in childhood: clinical and molecular features of two cases. Pediatr Hematol Oncol 2009; 26:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/9\">",
"      Rapanotti MC, Caruso R, Ammatuna E, et al. Molecular characterization of paediatric idiopathic hypereosinophilia. Br J Haematol 2010; 151:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/10\">",
"      Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124:1319.",
"     </a>",
"    </li>",
"    <li>",
"     Spry CJF. Idiopathic hypereosinophilic syndrome. In: Eosinophils: Biological and clinical aspects, Makino S, Fukuda T (Eds), CRC, Boca Raton 1992. p.403.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/12\">",
"      Ackerman SJ, Bochner BS. Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders. Immunol Allergy Clin North Am 2007; 27:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/13\">",
"      Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104:3038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/14\">",
"      Simon HU, Pl&ouml;tz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 1999; 341:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/15\">",
"      Vaklavas C, Tefferi A, Butterfield J, et al. 'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leuk Res 2007; 31:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/16\">",
"      Roche-Lestienne C, Lepers S, Soenen-Cornu V, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005; 19:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/17\">",
"      Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/18\">",
"      Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003; 54:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/19\">",
"      Bain BJ, Fletcher SH. Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome. Immunol Allergy Clin North Am 2007; 27:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/20\">",
"      Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 2006; 30:1201.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/22\">",
"      Albano F, Anelli L, Zagaria A, et al. Extramedullary molecular evidence of the 5'KIAA1509/3'PDGFRB fusion gene in chronic eosinophilic leukemia. Leuk Res 2008; 32:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/23\">",
"      Yoshida C, Takeuchi M, Sadahira Y. A novel t(1;8)(q25;p11.2) translocation associated with 8p11 myeloproliferative syndrome. Br J Haematol 2012; 156:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/24\">",
"      Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/25\">",
"      Griffin JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci U S A 2003; 100:7830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/26\">",
"      Safley AM, Sebastian S, Collins TS, et al. Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. Genes Chromosomes Cancer 2004; 40:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/27\">",
"      Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 2004; 104:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/28\">",
"      Jovanovic JV, Score J, Waghorn K, et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007; 109:4635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/29\">",
"      Score J, Curtis C, Waghorn K, et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006; 20:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/30\">",
"      Curtis CE, Grand FH, Musto P, et al. Two novel imatinib-responsive PDGFRA fusion genes in chronic eosinophilic leukaemia. Br J Haematol 2007; 138:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/31\">",
"      Walz C, Haferlach C, H&auml;nel A, et al. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Genes Chromosomes Cancer 2009; 48:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/32\">",
"      Elling C, Erben P, Walz C, et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011; 117:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/33\">",
"      Luppi M, Marasca R, Morselli M, et al. Clonal nature of hypereosinophilic syndrome. Blood 1994; 84:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/34\">",
"      Chang HW, Leong KH, Koh DR, Lee SH. Clonality of isolated eosinophils in the hypereosinophilic syndrome. Blood 1999; 93:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/35\">",
"      Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/36\">",
"      Roufosse F, Schanden&eacute; L, Sibille C, et al. Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome. Br J Haematol 2000; 109:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/37\">",
"      Rioux JD, Stone VA, Daly MJ, et al. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5q31-q33. Am J Hum Genet 1998; 63:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/38\">",
"      Collins MH, Blanchard C, Abonia JP, et al. Clinical, pathologic, and molecular characterization of familial eosinophilic esophagitis compared with sporadic cases. Clin Gastroenterol Hepatol 2008; 6:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/39\">",
"      Rosenfeld K, Stodell MA. Eosinophilic fasciitis in a father and son. Ann Rheum Dis 1994; 53:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/40\">",
"      Thomson GT, MacDougall B, Watson PH, Chalmers IM. Eosinophilic fasciitis in a pair of siblings. Arthritis Rheum 1989; 32:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/41\">",
"      Renston JP, Goldman ES, Hsu RM, Tomashefski JF Jr. Peripheral blood eosinophilia in association with sarcoidosis. Mayo Clin Proc 2000; 75:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/42\">",
"      Kim YJ, Dale JK, Noel P, et al. Eosinophilia is associated with a higher mortality rate among patients with autoimmune lymphoproliferative syndrome. Am J Hematol 2007; 82:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/43\">",
"      Aspinall AI, Pinto A, Auer IA, et al. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia. Blood Cells Mol Dis 1999; 25:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/44\">",
"      Smith KJ, Skelton HG, Drabick JJ, et al. Hypereosinophilia secondary to immunodysregulation in patients with HIV-1 disease. Arch Dermatol 1994; 130:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/45\">",
"      Paganelli R, Scala E, Mazzone AM, et al. Th2-type cytokines, hypereosinophilia, and interleukin-5 in HIV disease. Allergy 1997; 52:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/46\">",
"      Benfield GF, Asquith P. Blood eosinophilia and ulcerative colitis--influence of ethnic origin. Postgrad Med J 1986; 62:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/47\">",
"      Take M, Sekiguchi M, Hiroe M, et al. Clinical spectrum and endomyocardial biopsy findings in eosinophilic heart disease. Heart Vessels Suppl 1985; 1:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/48\">",
"      Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/49\">",
"      Chew CY, Ziady GM, Raphael MJ, et al. Primary restrictive cardiomyopathy. Non-tropical endomyocardial fibrosis and hypereosinophilic heart disease. Br Heart J 1977; 39:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/50\">",
"      Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101:4660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/51\">",
"      Pitini V, Arrigo C, Azzarello D, et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003; 102:3456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/52\">",
"      Gertz MA. Troponin in hematologic oncology. Leuk Lymphoma 2008; 49:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/53\">",
"      Zaky J, Caraang C, Yu R, El-Bialy A. Elevated troponins and the Churg-Strauss syndrome: a case report. J Cardiovasc Pharmacol Ther 2005; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/54\">",
"      Debl K, Djavidani B, Buchner S, et al. Time course of eosinophilic myocarditis visualized by CMR. J Cardiovasc Magn Reson 2008; 10:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/55\">",
"      Syed IS, Martinez MW, Feng DL, Glockner JF. Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. Int J Cardiol 2008; 126:e50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/56\">",
"      Wright BL, Leiferman KM, Gleich GJ. Eosinophil granule protein localization in eosinophilic endomyocardial disease. N Engl J Med 2011; 365:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/57\">",
"      Plastiras SC, Economopoulos N, Kelekis NL, Tzelepis GE. Magnetic resonance imaging of the heart in a patient with hypereosinophilic syndrome. Am J Med 2006; 119:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/58\">",
"      Wang JG, Mahmud SA, Thompson JA, et al. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood 2006; 107:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/59\">",
"      Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007; 109:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/60\">",
"      Moore PM, Harley JB, Fauci AS. Neurologic dysfunction in the idiopathic hypereosinophilic syndrome. Ann Intern Med 1985; 102:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/61\">",
"      Aida L, Parkhutik V, Tembl JI, et al. Embolism and impaired washout: a possible explanation of border zone strokes in hypereosinophilic syndrome. J Neurol Sci 2013; 325:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/62\">",
"      Kawata E, Kuroda J, Wada K, et al. Hypereosinophilic syndrome accompanied by Buerger's disease-like femoral arterial occlusions. Intern Med 2007; 46:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/63\">",
"      Sakuta R, Tomita Y, Ohashi M, et al. Idiopathic hypereosinophilic syndrome complicated by central sinovenous thrombosis. Brain Dev 2007; 29:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/64\">",
"      Numagami Y, Tomita T, Murakami K, et al. Sinus thrombosis in idiopathic hypereosinophilic syndrome causing fatal cerebral haemorrhage. J Clin Neurosci 2008; 15:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/65\">",
"      Spry CJ, Davies J, Tai PC, et al. Clinical features of fifteen patients with the hypereosinophilic syndrome. Q J Med 1983; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/66\">",
"      Liapis H, Ho AK, Brown D, et al. Thrombotic microangiopathy associated with the hypereosinophilic syndrome. Kidney Int 2005; 67:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/67\">",
"      Fauci AS, Harley JB, Roberts WC, et al. NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations. Ann Intern Med 1982; 97:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/68\">",
"      Chaine G, Davies J, Kohner EM, et al. Ophthalmologic abnormalities in the hypereosinophilic syndrome. Ophthalmology 1982; 89:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/69\">",
"      Leiferman KM, Gleich GJ, Peters MS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am 2007; 27:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/70\">",
"      McPherson T, Cowen EW, McBurney E, Klion AD. Platelet-derived growth factor receptor-alpha-associated hypereosinophilic syndrome and lymphomatoid papulosis. Br J Dermatol 2006; 155:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/71\">",
"      Schooley RT, Flaum MA, Gralnick HR, Fauci AS. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations. Blood 1981; 58:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/72\">",
"      Dulohery MM, Patel RR, Schneider F, Ryu JH. Lung involvement in hypereosinophilic syndromes. Respir Med 2011; 105:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/73\">",
"      Flaum MA, Schooley RT, Fauci AS, Gralnick HR. A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. I. Hematologic manifestations. Blood 1981; 58:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/74\">",
"      Parreira L, Tavares de Castro J, Hibbin JA, et al. Chromosome and cell culture studies in eosinophilic leukaemia. Br J Haematol 1986; 62:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/75\">",
"      Bain B. Philadelphia chromosome? Am J Hematol 2007; 82:414; author reply 414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/76\">",
"      Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003; 102:3093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/77\">",
"      Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Hematol 2004; 77:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/78\">",
"      Cogan E, Schanden&eacute; L, Crusiaux A, et al. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med 1994; 330:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/79\">",
"      Simon HU, Yousefi S, Dommann-Scherrer CC, et al. Expansion of cytokine-producing CD4-CD8- T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996; 183:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/80\">",
"      Kitano K, Ichikawa N, Mahbub B, et al. Eosinophilia associated with proliferation of CD(3+)4-(8-) alpha beta+ T cells with chromosome 16 anomalies. Br J Haematol 1996; 92:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/81\">",
"      de Lavareille A, Roufosse F, Schmid-Grendelmeier P, et al. High serum thymus and activation-regulated chemokine levels in the lymphocytic variant of the hypereosinophilic syndrome. J Allergy Clin Immunol 2002; 110:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/82\">",
"      Ravoet M, Sibille C, Roufosse F, et al. 6q- is an early and persistent chromosomal aberration in CD3-CD4+ T-cell clones associated with the lymphocytic variant of hypereosinophilic syndrome. Haematologica 2005; 90:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/83\">",
"      Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003; 121:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/84\">",
"      Bain BJ. Hypereosinophilia. Curr Opin Hematol 2000; 7:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/85\">",
"      Fridman A, Sagiv Sh, Shvidel L, Berrebi A. Reversible Horner syndrome caused by solitary plasmacytoma of second thoracic vertebrae. Leuk Lymphoma 2004; 45:2531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/24/30090/abstract/86\">",
"      Maric I, Robyn J, Metcalfe DD, et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007; 120:680.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2211 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-FB0AF5DF12-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30090=[""].join("\n");
var outline_f29_24_30090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19581555\">",
"      Expert consensus terminology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19581596\">",
"      - Hypereosinophilic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Theories of pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HES variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Myeloproliferative HES variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12440488\">",
"      Myeloproliferative neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - T cell lymphocytic variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Familial HES",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Idiopathic HES",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Overlap HES",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4769463\">",
"      - Gleich's syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22506766\">",
"      Churg-Strauss syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Associated HES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19581612\">",
"      Hypereosinophilia of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Signs and symptoms at presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neurologic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Thrombotic complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Ocular manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Skin disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      LABORATORY FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Initial studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hematologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Diagnosis of HES subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Diagnosis of myeloproliferative variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Diagnosis of L-HES",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Diagnosis of familial HES",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Diagnosis of overlap and associated forms of HES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Acute eosinophilic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Chronic myeloid or myelomonocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Systemic mastocytosis with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2211\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2211|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?23/29/24016\" title=\"algorithm 1\">",
"      Hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2211|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/5/17503\" title=\"diagnostic image 1\">",
"      HES cardiac findings MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/14/40174\" title=\"diagnostic image 2\">",
"      Ventricular thrombus HES Echo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2211|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/1/8213\" title=\"picture 1\">",
"      Eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/19/33079\" title=\"picture 2\">",
"      Chronic eosinophilic leukemia with FIP1L1-PDGFRA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40537\" title=\"picture 3\">",
"      BM findings in myeloproliferative HES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2211|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/19/26940\" title=\"table 1\">",
"      Clinical and molecular features of HES variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27688?source=related_link\">",
"      Causes of pulmonary eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27177?source=related_link\">",
"      Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4618?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8712?source=related_link\">",
"      Differential diagnosis of peripheral nerve and muscle disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=related_link\">",
"      Diseases with eosinophilic involvement of specific organs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12361?source=related_link\">",
"      Echocardiography in detection of intracardiac sources of embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=related_link\">",
"      Endomyocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=related_link\">",
"      Etiology of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7546?source=related_link\">",
"      Lymphomatoid papulosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23719?source=related_link\">",
"      Pathogenesis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25898?source=related_link\">",
"      Treatment of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_24_30091="Eligibility criteria allo-HCT";
var content_f29_24_30091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F88755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F88755&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General eligibility criteria for allogeneic hematopoietic cell transplantation (allo-HCT)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Disease-related indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suitable donor available",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Karnofsky performance status &ge;70 for a myeloablative HCT or &ge;50 for a nonmyeloablative HCT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal function:",
"        <br/>",
"        <ul>",
"         <li>",
"          While no specific cutoff is universally used, many centers limit allo-HCT&nbsp;to those with a serum creatinine &lt;2 mg/dL (177 micromol/L) or CrCl &gt;50",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac reserve:",
"        <br/>",
"        <ul>",
"         <li>",
"          LVEF &gt;35",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary function:",
"        <br/>",
"        <ul>",
"         <li>",
"          A corrected DLCO &gt;35 percent",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Liver function:",
"        <br/>",
"        <ul>",
"         <li>",
"          No frank cirrhosis of the liver",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adequate psychosocial and financial support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        While no specific age cutoff is universally used, many centers limit myeloablative allo-HCT to patients &lt;55 years and reduced intensity allo-HCT to patients &lt;75 years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LVEF: left ventricular ejection fraction; DLCO: diffusing capacity of the lungs for carbon monoxide.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30091=[""].join("\n");
var outline_f29_24_30091=null;
var title_f29_24_30092="Local anesthetics used for regional anesthesia";
var content_f29_24_30092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Local anesthetics used for regional anesthesia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Agent",
"      </td>",
"      <td class=\"subtitle1\">",
"       Speed on onset",
"      </td>",
"      <td class=\"subtitle1\">",
"       Duration",
"      </td>",
"      <td class=\"subtitle1\">",
"       Maximum dose plain (mg/kg)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Maximum dose with vasoconstrictor (mg/kg)",
"      </td>",
"      <td class=\"subtitle1\">",
"       pKa (25&deg;C)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Ester agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Procaine",
"      </td>",
"      <td>",
"       Slow",
"      </td>",
"      <td>",
"       Short",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2-Chloroprocaine",
"      </td>",
"      <td>",
"       Rapid",
"      </td>",
"      <td>",
"       Short",
"      </td>",
"      <td>",
"       10",
"      </td>",
"      <td>",
"       15",
"      </td>",
"      <td>",
"       9.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tetracaine",
"      </td>",
"      <td>",
"       Slow",
"      </td>",
"      <td>",
"       Intermediate",
"      </td>",
"      <td>",
"       1.5",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"      <td>",
"       8.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"6\">",
"       Amide agents",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lidocaine",
"      </td>",
"      <td>",
"       Fast",
"      </td>",
"      <td>",
"       Intermediate",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       7.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Mepivacaine",
"      </td>",
"      <td>",
"       Slow",
"      </td>",
"      <td>",
"       Intermediate",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       7",
"      </td>",
"      <td>",
"       7.9",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bupivacaine",
"      </td>",
"      <td>",
"       Slow",
"      </td>",
"      <td>",
"       Long",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       8.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Levobupivacaine",
"      </td>",
"      <td>",
"       Slow",
"      </td>",
"      <td>",
"       Long",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       8.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ropivacaine",
"      </td>",
"      <td>",
"       Slow",
"      </td>",
"      <td>",
"       Long",
"      </td>",
"      <td>",
"       2.5",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       8.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Prilocaine",
"      </td>",
"      <td>",
"       Fast",
"      </td>",
"      <td>",
"       Intermediate",
"      </td>",
"      <td>",
"       5",
"      </td>",
"      <td>",
"       8",
"      </td>",
"      <td>",
"       7.9",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: McLure HA, Rubin AP. Review of local anesthetics. Minerva Anesthesiol 2005; 71:59.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30092=[""].join("\n");
var outline_f29_24_30092=null;
var title_f29_24_30093="Chromosomal abnormalities";
var content_f29_24_30093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recurring chromosomal abnormalities in adults with myelodysplastic syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Disease",
"      </td>",
"      <td class=\"subtitle1\">",
"       Chromosome abnormality",
"      </td>",
"      <td class=\"subtitle1\">",
"       Frequency",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Involved genes*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Consequence",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"11\">",
"       <strong>",
"        MDS unbalanced",
"       </strong>",
"      </td>",
"      <td>",
"       +8",
"      </td>",
"      <td>",
"       10 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       -7/del(7q)",
"      </td>",
"      <td>",
"       10 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       -5/del(5q)",
"      </td>",
"      <td>",
"       10 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       del(20q)",
"      </td>",
"      <td>",
"       5 to 8 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       -Y",
"      </td>",
"      <td>",
"       5 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       i(17p)",
"      </td>",
"      <td>",
"       3 to 5 percent",
"      </td>",
"      <td>",
"       TP53",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       Loss of function",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       -13/del(13q)",
"      </td>",
"      <td>",
"       3 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       del(11q)",
"      </td>",
"      <td>",
"       3 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       del(12p)/t(12p)",
"      </td>",
"      <td>",
"       3 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       del(9q)",
"      </td>",
"      <td>",
"       1 to 2 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       idic(X)(q13)",
"      </td>",
"      <td>",
"       1 to 2 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       <strong>",
"        Balanced",
"       </strong>",
"      </td>",
"      <td>",
"       t(1;3)(p36.3;q21)",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"      <td>",
"       PRDM16",
"      </td>",
"      <td>",
"       RPN1",
"      </td>",
"      <td>",
"       Deregulation of PRDM16 - transcriptional activation?",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       t(2;11)(p21;q23)/t(11q23)",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       MLL",
"      </td>",
"      <td>",
"       MLL fusion protein - altered transcriptional regulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       inv(3)(q21q26.2)",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"      <td>",
"       RPN1",
"      </td>",
"      <td>",
"       MDS1/EVI1",
"      </td>",
"      <td>",
"       Fusion protein",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       t(6;9)(p23;q34)",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"      <td>",
"       DEK",
"      </td>",
"      <td>",
"       NUP214",
"      </td>",
"      <td>",
"       Fusion protein - nuclear pore protein",
"      </td>",
"     </tr>",
"     <tr>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       <strong>",
"        Therapy-related MDS",
"       </strong>",
"      </td>",
"      <td>",
"       -7/del(7q)",
"      </td>",
"      <td>",
"       50 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       -5/del(5q)",
"      </td>",
"      <td>",
"       40 to 45 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       dic(5;17)(q11.1-13;p11.1-13)",
"      </td>",
"      <td>",
"       5 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       TP53",
"      </td>",
"      <td>",
"       Loss of function, DNA damage response",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       der(1;7)(q10;p10)",
"      </td>",
"      <td>",
"       3 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       t(3;21)(q26.2;q22.1)",
"      </td>",
"      <td>",
"       2 percent",
"      </td>",
"      <td>",
"       RPL22L1",
"      </td>",
"      <td>",
"       RUNX1",
"      </td>",
"      <td>",
"       RUNX1 fusion protein - altered transcriptional regulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       t(11;16)(q23;p13.3)/t(11q23)",
"      </td>",
"      <td>",
"       3 percent",
"      </td>",
"      <td>",
"       MLL",
"      </td>",
"      <td>",
"       CREBBP",
"      </td>",
"      <td>",
"       MLL fusion protein - altered transcriptional regulation",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Genes are listed in order of citation in the karyotype, eg, for the t(11;16), MLL is at 11q23 and CBP at 16p13.3.",
"    </div>",
"    <div class=\"reference\">",
"     Source: Vardiman, JW, Brunning, RD, Arber, DA, et al. Introduction and overview of the classification of the myeloid neoplasms. In: WHO classification of tumors of hematopoietic and lymphoid tissues, Swerdlow, SH, Campo, E, Harris, NL, et al. (Eds), WHO Press, 2008. p.18.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30093=[""].join("\n");
var outline_f29_24_30093=null;
var title_f29_24_30094="Pericardial effusion with tamponade subcostal view";
var content_f29_24_30094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/64027/subpref2_conv.mp4?title=Pericardial+effusion+with+tamponade+subcostal+view\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcostal four chamber view from a two-dimensional echocardiogram shows a massive pericardial effusion (PE) surrounding the left ventricle (LV), right atrium (RA), and right ventricle (RV) which is strikingly reduced and shows diastolic collapse. The patient had severe hemodynamic compromise and tamponade physiology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ralph Shabetai, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30094=[""].join("\n");
var outline_f29_24_30094=null;
var title_f29_24_30095="LLL atelectasis CT";
var content_f29_24_30095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78260&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT scan of left lower lobe atelectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronic complete lobar atelectasis of the left lower lobe. Triangular opacity in left paraspinal location (arrow) obscures the lateral contour of the descending aorta. Cylindrical bronchiectasis is seen in the affected lobe and accounts for the multiple small lucencies permeating the atelectatic left lower lobe. These findings are the result of necrotizing pneumonia in the patient's distant past.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_24_30095=[""].join("\n");
var outline_f29_24_30095=null;
